Paclitaxel
Small molecule targets SPARC, TLR4 via activation
Regulatory milestones approvals, filings & regulatory actions · 14 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PACLITAXEL | — | 2023-11-21 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | ABRAXANE | — | 2007-02-15 – 2019-12-06 | fda.gov ↗ |
| Label expansions (7) | US (FDA) | TAXOL | — | 1994-04-13 – 2000-06-20 | fda.gov ↗ |
| Approved | EU (EMA) | Paxene | — | 1999-07-19 | europa.eu ↗ |
| Approved | US (FDA) | TAXOL | — | 1992-12-29 | fda.gov ↗ |
Trials 2,769 · started per year
Also used as a comparator or background therapy in 2,011 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT06326736 Background | Apr 2024 → Dec 2025 overdue | malignant pancreatic neoplasm | Jinling Hospital, China | Recruiting | No outcome recorded |
| Phase 0 | NCT05831033 Background | May 2023 → Feb 2027 expected | cancer | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT05691010 Background | Jan 2023 → Jan 2027 expected | endometrial carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05648994 Background | Dec 2022 → Feb 2024 | cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05415709 Background | Jun 2022 → Dec 2026 expected | fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian endometrioid adenocarcinoma +3 | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05053750 Background | Dec 2021 → Feb 2027 expected | fallopian tube neoplasm, malignant epithelial tumor of ovary, primary peritoneal carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05438797 Background | Apr 2021 → Apr 2024 | digestive system cancer | Sizhen Wang | Unknown | No outcome recorded |
| Phase 0 | NCT03519308 Background | Jul 2020 → Apr 2022 | malignant pancreatic neoplasm | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
| Phase 0 | NCT03940001 Background | May 2019 → May 2021 | esophageal squamous cell carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT02550327 Background | Jan 2016 → Jun 2021 | pancreatic adenocarcinoma | Baylor Research Institute | Completed | No outcome recorded |
| Phase 1279 trials | ||||||
| Phase 1 | NCT07594548 Background | Sep 2027 → Sep 2030 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07300475 Background | Aug 2026 → May 2030 expected | triple-negative breast carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07699757 Background | Jul 2026 → Apr 2029 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07335380 Background | Apr 2026 → Mar 2031 expected | oral cavity squamous cell carcinoma | NYU Langone Health | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07348107 Background | Feb 2026 → Mar 2027 expected | pancreatic ductal adenocarcinoma | Daniel Breadner | Not yet recruiting | No outcome recorded |
| Show all 279 trials opens the full record — a long page | ||||||
| Phase 1/2218 trials | ||||||
| Phase 1/2 | NCT06592664 Background | Jan 2030 → Jan 2035 | pancreatic ductal adenocarcinoma | Lisata Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT07705919 Background | Sep 2026 → Dec 2027 expected | pancreatic ductal adenocarcinoma | Ohio State University Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07678593 Background | Sep 2026 → Nov 2027 expected | pancreatic ductal adenocarcinoma | Genfleet Therapeutics (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07701486 Background | Aug 2026 → Aug 2027 expected | pancreatic ductal adenocarcinoma | Theriva Biologics SL | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07637851 Background | Aug 2026 → Sep 2028 expected | ovarian cancer | ARCAGY/ GINECO GROUP | Not yet recruiting | No outcome recorded |
| Show all 218 trials opens the full record — a long page | ||||||
| Phase 2813 trials | ||||||
| Phase 2 | NCT06708455 Background | Mar 2027 → Mar 2029 expected | metastatic melanoma | Rapa Therapeutics LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07346196 Background | Feb 2027 → Aug 2031 expected | squamous cell carcinoma | University of Chicago | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07281417 Background | Nov 2026 → Dec 2030 expected | nasal cavity and paranasal sinus squamous cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT07610525 Background | Nov 2026 → Jan 2029 expected | triple-negative breast carcinoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07234877 Background | Nov 2026 → Jan 2032 expected | non-small cell lung carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting | No outcome recorded |
| Show all 813 trials opens the full record — a long page | ||||||
| Phase 2/363 trials | ||||||
| Phase 2/3 | NCT07365319 Background | Jun 2026 → Dec 2035 expected | non-small cell lung carcinoma | Eikon Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07554456 Comparator | Jun 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07662811 Comparator | Jun 2026 → Dec 2027 expected | non-small cell lung carcinoma | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07662395 Background | May 2026 → Jan 2030 expected | — | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07318883 Background | Mar 2026 → Jan 2031 expected | non-small cell squamous lung carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07063745 Comparator | Jan 2026 → Aug 2031 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07251062 Comparator | Dec 2025 → Dec 2029 expected | esophageal squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07076121 Background | Oct 2025 → May 2029 expected | pancreatic ductal adenocarcinoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06926868 Comparator | Sep 2025 → Mar 2028 expected | breast neoplasm | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07472153 Comparator | Jul 2025 → Jun 2030 expected | cervical cancer | N.N. Alexandrov National Cancer Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06712316 Background | Jan 2025 → Feb 2029 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06601283 Background | Nov 2024 → Nov 2026 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06755515 Background | Sep 2024 → Sep 2028 expected | cervical cancer | Shandong New Time Pharmaceutical Co., LTD | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT06203600 Background | Jun 2024 → Oct 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06321068 Background | Apr 2024 → May 2025 | endometrial cancer | Bio-Thera Solutions | Terminated | No outcome recorded |
| Phase 2/3 | NCT06354530 Background | Mar 2024 → Dec 2025 overdue | esophageal squamous cell carcinoma | Army Medical Center of PLA | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06214572 Comparator | Mar 2024 → Jul 2029 expected | gallbladder cancer | Tata Memorial Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06161025 Comparator | Feb 2024 → Feb 2028 expected | — | Daiichi Sankyo | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05800015 Background | Aug 2023 → Jan 2030 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05870748 Comparator | Jul 2023 → Aug 2025 | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Sutro Biopharma, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT05747794 Background | May 2023 → Oct 2026 expected | breast carcinoma | Immutep S.A.S. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05889390 Background | Feb 2023 → Oct 2025 overdue | Her2-receptor negative breast cancer | Semmelweis University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05254171 Background | Aug 2022 → Aug 2026 overdue | pancreatic ductal adenocarcinoma | Panbela Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05213312 Background | Jun → Nov 2022 | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05255302 Background | May 2022 → May 2025 overdue | non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05427383 Background | Apr 2022 → Nov 2025 overdue | gastric cancer | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05189067 Comparator | Jan 2022 → Jan 2025 | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05002127 Background | Jan 2022 → May 2024 overdue | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | ALX Oncology Inc. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05255653 Background | Nov 2021 → Jan 2030 expected | endometrial cancer | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04037241 Background | Nov 2021 → Jan 2022 | malignant pancreatic neoplasm | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04862585 Background | Oct 2021 → Jun 2024 | breast carcinoma in situ, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT05189535 Background | Oct 2021 → Sep 2023 | female breast carcinoma, peripheral neuropathy | Ain Shams University | Completed | No outcome recorded |
| Phase 2/3 | NCT05002686 Background | Aug 2021 → Aug 2023 | gastric cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04907344 Background | Jun 2021 → Jun 2025 | triple-negative breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04499924 Background | Mar 2021 → Apr 2024 | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT03651206 Comparator | Jul 2020 → Jun 2027 expected | ovarian carcinosarcoma, uterine carcinosarcoma | ARCAGY/ GINECO GROUP | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04290793 Comparator | Mar 2020 → Dec 2026 expected | breast cancer | Hebei Medical University Fourth Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03604991 Background | May 2019 → Dec 2026 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 2/3 | NCT05268692 Comparator | Jan 2019 → Dec 2025 overdue | pancreatic adenocarcinoma | Kochi University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03410693 Comparator | May 2018 → Oct 2020 | transitional cell carcinoma | Bayer | Completed | No outcome recorded |
| Phase 2/3 | NCT03580395 Background | Jun 2017 → Jul 2022 | breast cancer | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT03081143 Comparator | May 2017 → May 2026 | gastroesophageal cancer | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2/3 | NCT02502266 Comparator | May 2016 → Jun 2023 overdue | fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma +7 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03150576 Background | May 2016 → Jun 2024 overdue | breast cancer | Cambridge University Hospitals NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02777788 Comparator | Sep 2014 → Dec 2019 | cancer | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 2/3 | NCT02159820 Comparator | Jun 2014 → Jun 2024 | ovarian cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02101788 Comparator | Apr 2014 → Apr 2019 | borderline ovarian serous tumor, micropapillary serous carcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT02065687 Background | Mar 2014 → Apr 2019 | endometrial clear cell adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma | Gynecologic Oncology Group | Unknown | No outcome recorded |
| Phase 2/3 | NCT01641939 Comparator | Sep 2012 → Jun 2015 | gastric cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2/3 | NCT01572727 Background | Aug 2012 → Jun 2015 | female breast carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT02442362 Comparator | Jan 2012 → Jan 2014 | gastric cancer | The First People's Hospital of Changzhou | Completed | No outcome recorded |
| Phase 2/3 | NCT01426880 Background | Aug 2011 → May 2013 | HER2 positive breast carcinoma, breast mucinous carcinoma, female breast carcinoma, inflammatory breast carcinoma +1 | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT01196741 Comparator | Mar 2011 → Nov 2012 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | University College, London | Completed | No outcome recorded |
| Phase 2/3 | NCT01506856 Comparator | May 2010 → Feb 2021 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Gynecologic Oncology Trial & Investigation Consortium | Completed | No outcome recorded |
| Phase 2/3 | NCT01057069 Comparator | Jan 2010 → Jun 2023 overdue | breast cancer | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00507429 Comparator | Aug 2007 → Oct 2011 | thyroid gland undifferentiated (anaplastic) carcinoma | Mateon Therapeutics | Terminated | No outcome recorded |
| Phase 2/3 | NCT00473889 Background | May 2007 → Dec 2008 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2/3 | NCT00752115 Comparator | Feb 2007 → Mar 2009 | non-small cell lung carcinoma | Hamamatsu University | Completed | No outcome recorded |
| Phase 2/3 | NCT00245154 Background | Nov 2005 → Jul 2008 | lung cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2/3 | NCT00337532 Comparator | May 2005 → Jun 2007 | head and neck cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2/3 | NCT00021060 Background | Aug 2002 → Sep 2006 | lung adenocarcinoma, lung large cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT00006229 Background | Apr 2000 → Dec 2003 | lung cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2/3 | NCT00003880 Background | Feb 1999 → Aug 2001 | ovarian cancer, primary peritoneal carcinoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3546 trials | ||||||
| Phase 3 | NCT07441681 Comparator | Jan 2027 → Nov 2035 expected | head and neck squamous cell carcinoma, hypopharyngeal carcinoma, lip and oral cavity carcinoma, oropharyngeal carcinoma | NRG Oncology | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07684612 Comparator | Sep 2026 → May 2030 expected | ovarian neoplasm | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05411237 Comparator | Sep 2026 → Sep 2029 expected | HIV infectious disease, Kaposi's sarcoma | AIDS Malignancy Consortium | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07621601 Comparator | Jul 2026 → Dec 2030 expected | esophageal squamous cell carcinoma | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07706985 Comparator | Jul 2026 → Jul 2030 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Show all 546 trials opens the full record — a long page | ||||||
| Phase 425 trials | ||||||
| Phase 4 | NCT07652515 Background | Aug 2026 → Aug 2030 expected | endometrial cancer | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07302841 Background | Jan 2026 → Jun 2027 expected | pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07093931 Background | Aug 2025 → Aug 2027 expected | breast cancer | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06388135 Comparator | May 2024 → May 2026 overdue | esophageal squamous cell carcinoma | Yang Jianjun, PhD | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06276933 Background | Feb 2024 → Nov 2025 overdue | lung cancer | Tongji University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06230055 Background | Jan 2024 → Jan 2026 overdue | Her2-receptor negative breast cancer, malignant leptomeningeal tumor | Fudan University | Recruiting | No outcome recorded |
| Phase 4 | NCT06169410 Background | Dec 2023 → Dec 2025 | gastric cancer | Yang Jianjun, PhD | Unknown | No outcome recorded |
| Phase 4 | NCT05730777 Background | Feb → Jul 2023 | chemotherapy-induced toxicity | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05583188 Background | Feb 2023 → Feb 2024 | non-small cell lung carcinoma | Galvanize Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT05603065 Comparator | Oct 2022 → Oct 2023 | esophageal squamous cell carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT05033769 Comparator | Mar 2021 → Jul 2023 | female breast carcinoma | Institut fuer Frauengesundheit | Unknown | No outcome recorded |
| Phase 4 | NCT04164797 Background | Nov 2019 → Jul 2021 | esophageal cancer | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT03986528 Comparator | Aug 2019 → Mar 2022 | non-small cell lung carcinoma | Jie Li | Unknown | No outcome recorded |
| Phase 4 | NCT03794778 Comparator | Mar 2019 → Mar 2024 | — | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT03092986 Comparator | Jan 2017 → Jun 2018 | non-small cell lung carcinoma | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT02688803 Comparator | Aug 2016 → Oct 2017 | breast cancer | Ottawa Hospital Research Institute | Terminated | No outcome recorded |
| Phase 4 | NCT02812992 Comparator | Jun 2016 → Feb 2020 | pancreatic adenocarcinoma | AIO-Studien-gGmbH | Completed | No outcome recorded |
| Phase 4 | NCT02419742 Background | Aug 2015 → Jun 2021 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT02207361 Background | Dec 2013 → Nov 2016 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01706120 Background | Oct 2012 → Dec 2024 | ovarian cancer | National Cancer Institute, Naples | Unknown | No outcome recorded |
| Phase 4 | NCT01501487 Comparator | Oct 2011 → Feb 2016 | breast cancer | Agendia | Completed | No outcome recorded |
| Phase 4 | NCT01317615 Background | Apr 2011 → Mar 2015 | large cell carcinoma, neuroendocrine neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01156961 Background | Oct 2010 → Dec 2012 | breast cancer | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 4 | NCT01094184 Background | Mar 2010 → Dec 2015 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00606515 Comparator | Feb → Oct 2008 | cancer | Shandong Luye Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable55 trials | ||||||
| — | NCT07552402 Comparator | Jun 2026 → Dec 2027 expected | gastroesophageal junction adenocarcinoma | Harbin Medical University | Recruiting | No outcome recorded |
| — | NCT07337096 Background | Jan 2026 → Dec 2027 expected | non-small cell lung carcinoma | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT06975644 Background | Sep 2025 → Sep 2026 expected | triple-negative breast carcinoma | Zhejiang Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07139587 Background | Sep 2025 → Aug 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Qingxia Li | Not yet recruiting | No outcome recorded |
| — | NCT06977594 Background | Jun 2025 → May 2027 expected | cervical cancer, endometrial cancer, ovarian cancer | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06466382 Comparator | Mar 2025 → Mar 2027 expected | fallopian tube neoplasm, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma | Swiss GO Trial Group | Recruiting | No outcome recorded |
| — | NCT06878196 Background | Mar 2025 → Dec 2028 expected | cervical cancer | Obstetrics & Gynecology Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| — | NCT06876636 Background | Mar → Dec 2025 overdue | breast carcinoma | Xijing Hospital | Active not recruiting | No outcome recorded |
| — | NCT06636591 Background | Dec 2024 → Jan 2026 | Her2-receptor negative breast cancer, female breast carcinoma | Fudan University | Completed | No outcome recorded |
| — | NCT06922279 Background | Nov 2024 → Oct 2029 expected | gastroesophageal cancer | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Active not recruiting | No outcome recorded |
| — | NCT06603974 Background | Oct 2024 → Jul 2026 overdue | gastric cancer | Xijing Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06607926 Background | Oct 2024 → Jun 2025 overdue | non-small cell lung carcinoma | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
| — | NCT06867146 Comparator | Oct 2024 → Dec 2026 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Active not recruiting | No outcome recorded |
| — | NCT06649448 Background | Oct 2024 → Dec 2025 overdue | neutropenia | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| — | NCT06102252 Comparator | Aug 2024 → Nov 2025 | endometrial carcinoma | Sohag University | Completed | No outcome recorded |
| — | NCT06292286 Background | Nov 2023 → Dec 2026 expected | ovarian carcinoma | The University of Hong Kong | Recruiting | No outcome recorded |
| — | NCT05869474 Background | Aug 2023 → Dec 2027 expected | malignant pancreatic neoplasm | Changhai Hospital | Recruiting | No outcome recorded |
| — | NCT05834413 Background | May 2023 → Jun 2027 expected | lung cancer | Shanghai University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT05601323 Background | Jan 2023 → May 2027 expected | pancreas disorder | SONIRE Therapeutics Inc. | Active not recruiting | No outcome recorded |
| — | NCT05561699 Background | Sep 2022 → Sep 2024 | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT06048926 Background | Jul 2022 → Jul 2025 overdue | esophageal squamous cell carcinoma | The First Affiliated Hospital with Nanjing Medical University | Enrolling by invitation | No outcome recorded |
| — | NCT05378334 Background | Jun 2022 → Sep 2027 expected | non-small cell lung carcinoma | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT05341141 Background | Jun 2022 → Aug 2026 overdue | breast cancer | Peking University | Recruiting | No outcome recorded |
| — | NCT05287308 Comparator | Mar 2022 → Sep 2027 expected | breast cancer | Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT07407231 Background | Sep 2021 → Sep 2024 overdue | pancreatic exocrine neoplasm | Institute of Oncology Ljubljana | Recruiting | No outcome recorded |
| — | NCT04950400 Background | Jul 2021 → Dec 2023 | non-small cell lung carcinoma | Beijing Chest Hospital | Unknown | No outcome recorded |
| — | NCT07115095 Background | Jan 2021 → Jan 2023 | HER2 positive breast carcinoma | Nanlin Li | Completed | No outcome recorded |
| — | NCT04699539 Background | Dec 2020 → Aug 2025 | — | Changhai Hospital | Completed | No outcome recorded |
| — | NCT04481256 Background | Nov 2020 → Sep 2025 overdue | esophageal cancer, squamous cell carcinoma | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| — | NCT04603586 Background | Nov 2020 → Aug 2025 | — | Changhai Hospital | Completed | No outcome recorded |
| — | NCT04471480 Background | Sep 2020 → Aug 2022 | esophageal squamous cell carcinoma | Dong Wang | Unknown | No outcome recorded |
| — | NCT04181645 Background | Jun 2019 → Dec 2021 | pancreatic ductal adenocarcinoma | RenJi Hospital | Completed | No outcome recorded |
| — | NCT03756090 Background | Dec 2018 → Dec 2019 | breast cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT06190600 Background | Oct 2018 → Mar 2020 overdue | female breast carcinoma | The Greater Poland Cancer Centre | Active not recruiting | No outcome recorded |
| — | NCT03443921 Comparator | Mar 2018 → Mar 2019 | malignant pancreatic neoplasm, pancreatic exocrine neoplasm | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT02923193 Background | Feb 2017 → May 2020 | peripheral arterial disease | Shockwave Medical, Inc. | Completed | No outcome recorded |
| — | NCT02988921 Background | Oct 2016 → Jan 2025 overdue | esophageal cancer, gastroesophageal junction adenocarcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| — | NCT02921022 Background | Oct 2016 → Oct 2026 expected | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| — | NCT01821833 Background | May 2016 → Jan 2018 | breast cancer, ovarian neoplasm | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| — | NCT04324346 Background | Apr 2016 → Feb 2021 | — | Swedish Red Cross University College | Completed | No outcome recorded |
| — | NCT02492867 Background | Jan 2016 → Nov 2021 | non-small cell lung carcinoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| — | NCT02640053 Background | Dec 2015 → Sep 2017 | breast carcinoma | Academic and Community Cancer Research United | Completed | No outcome recorded |
| — | NCT02457039 Comparator | Oct 2015 → Dec 2018 | breast cancer, chemotherapy-induced neuropathy, cognitive impairment with or without cerebellar ataxia, drug-induced mental disorder | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT03690323 Background | Apr 2015 → Nov 2019 | pancreatic exocrine neoplasm | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| — | NCT02194738 Background | Sep 2014 → Sep 2026 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| — | NCT02195336 Background | Aug 2014 → Jun 2016 | non-small cell lung carcinoma | Karl Kölbeck | Unknown | No outcome recorded |
| — | NCT05173857 Comparator | Mar 2014 → Jul 2017 | kidney disorder, vascular disorder | Skane University Hospital | Completed | No outcome recorded |
| — | NCT01891123 Comparator | Jun 2013 → Jun 2016 | breast cancer, nasopharyngeal carcinoma, non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT03243825 Background | Nov 2012 → Jun 2015 | cervical cancer | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| — | NCT01599078 Comparator | Jan 2012 → Jan 2013 | peripheral arterial disease | Midwest Cardiovascular Research Foundation | Unknown | No outcome recorded |
| — | NCT01393080 Background | Mar 2011 → Dec 2016 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT01144442 Background | Jul 2010 → Sep 2013 | fallopian tube cancer, ovarian cancer, peritoneal carcinoma | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| — | NCT01209520 Background | Jul 2009 → Dec 2013 | non-small cell lung carcinoma | University of Miami | Completed | No outcome recorded |
| — | NCT00656669 Background | Apr 2008 → Sep 2010 | breast cancer | Indiana University | Completed | No outcome recorded |
| — | NCT00544167 Background | May 2007 → Jan 2008 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT07319910 Background | — | pancreatic adenocarcinoma | NovoCure Ltd. | Temporarily not available | No outcome recorded |
| — | NCT03756311 Background | — | lung cancer, prostate cancer | NanOlogy, LLC | No longer available | No outcome recorded |
Press releases naming this drug 23 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-06-04 | Novartis Pharmaceuticals | Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy novartis.com ↗ |
| 2021-03-05 | Gilead Sciences | U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy gilead.com ↗ |
| 2020-08-06 | Roche Global Development | Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer roche.com ↗ |
| 2020-06-18 | Roche Global Development | Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer roche.com ↗ |
| 2019-12-04 | Roche Global Development | FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer roche.com ↗ |
| 2019-08-29 | Roche Global Development | European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗ |
| 2019-06-28 | Roche Global Development | CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗ |
| 2019-03-11 | Roche Global Development | Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane roche.com ↗ |
| 2019-03-11 | Roche Global Development | FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗ |
| 2019-01-17 | Roche Global Development | FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer roche.com ↗ |
| 2018-11-13 | Roche Global Development | FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗ |
| 2018-10-22 | Roche Global Development | Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone roche.com ↗ |
| 2018-10-20 | Roche Global Development | Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer roche.com ↗ |
| 2018-08-27 | Gilead Sciences | Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy gilead.com ↗ |
| 2018-07-02 | Roche Global Development | Phase III IMpassion130 study showed Roche's Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer roche.com ↗ |
| 2018-06-29 | Gilead Sciences | European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy gilead.com ↗ |
| 2018-06-02 | Roche Global Development | Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer roche.com ↗ |
| 2018-05-29 | Roche Global Development | Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone roche.com ↗ |
| 2018-03-20 | Roche Global Development | Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer roche.com ↗ |
| 2018-01-22 | Takeda | European Commission Approves ADCETRIS ® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy – Providing an Innovative Treatment Option to Patients takeda.com ↗ |
| 2017-10-18 | Gilead Sciences | Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy gilead.com ↗ |
| 2017-08-02 | AbbVie | U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) -- A Serious, Potentially Life-Threatening Condition -- After Failure of One or More Lines of Systemic Therapy abbvie.com ↗ |
| 2002-06-12 | AbbVie | ImmunoGen, Inc. Taxane Derivatives Show Greater Potency Than Taxol(R) Against Both Taxane-Responsive and Multi-Drug-Resistant Cancer Cell Lines abbvie.com ↗ |
Evidence & citations 100 cited values
Every value below carries the sentence it was read from. 4,822 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paclitaxel | “Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane...” NCT05415215 ↗3602“Patients with stage IV non-small cell lung cancer and stable disease after two cycles of cisplatin (P) and gemcitabine (G) (P day1 (d(1)): 75 mg/m(2), G: 1250 mg/m(2) d(1) and...” PMID 19155999 ↗ Mar 2009 “Camrelizumab 200 mg (Day 1) intravenous infusion (IV) and Paclitaxel Albumin - bound 125 mg/m² (Day 1, Day 8) IV and Carboplatin AUC 4 (Day 1) IV, with a 21-day cycle for 2...” NCT07432087 ↗ “The SAVAL trial is a prospective, multicenter, randomized trial of patients with CLTI and infrapopliteal artery lesions with total lesion length ⩽ 140 mm, stenosis ⩾ 70%, and...” PMID 37844137 ↗ Oct 2023 “We performed a prospective, randomized, phase III, intergroup trial to compare carboplatin plus paclitaxel (TC; area under the curve [AUC] 5 and 175 mg/m(2), respectively) with...” PMID 20733132 ↗ Aug 2010 “Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine,...” NCT01156753 ↗ “Squamous cell carcinoma: Paclitaxel (175mg/m²) or Docetaxel (60-75 mg/m²) or Nab-paclitaxel (260mg/m²) plus Carboplatin (AUC=5)/Cisplatin (75 mg/m²) (to be determined by...” NCT07608159 ↗ “Acceptable histology-specific PDC regimens include carboplatin plus paclitaxel or nab-paclitaxel (any histology), carboplatin/cisplatin plus pemetrexed (nonsquamous),...” NCT06865339 ↗ “Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment...” NCT03301454 ↗ “Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam...” NCT05255653 ↗ “platinum-based doublet chemotherapy (carboplatin [area under the curve ≤700 mg] plus pemetrexed [500 mg/m2 intravenous infusion every 3 weeks] or carboplatin [on day 1; area...” PMID 39486424 ↗ Oct 2024 “All patients will receive a one-cycle lead-in of carboplatin (with or without) paclitaxel followed by three cycles of carboplatin, paclitaxel, and pembrolizumab prior to...” NCT05952453 ↗ “After induction with sintilimab plus paclitaxel, cisplatin, and nimotuzumab, participants will receive concurrent chemoradiotherapy with nimotuzumab, followed by maintenance...” NCT07310771 ↗ “cycle 1, Paclitaxel 75mg/ m2 diluted with 3000ml normal saline heated up to a fixed temperature of 43°C circulate continuously for 60min at a speed of 400-500ml/h; cycle 2...” NCT02960061 ↗ “Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on...” NCT04421547 ↗ “The cohort A (borderline resectable) and cohort B (locally advanced) both received treatment with gemcitabine, albumin paclitaxel (administered on days 1, 8, and 15, with 4...” NCT07208539 ↗ “Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a...” NCT03117049 ↗ “The patients were randomly assigned to receive 3 cycles of paclitaxel-cisplatin-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy or concurrent...” PMID 40531520 ↗ Aug 2025 “Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600...” NCT05569811 ↗ “This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating...” NCT01555853 ↗ “The histological type of squamous cells carcinoma, which is the large majority of penile cancer, led Pagliaro et al. [10] to explore a combination of Paclitaxel, Ifosfamide and...” NCT02014831 ↗ “four cycles of docetaxel and cyclophosphamide or four cycles of weekly paclitaxel Combined with Trastuzumab followed by standard endocrine therapy( aromatase inhibitors or...” NCT07213206 ↗ “Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant...” NCT02249013 ↗ “Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by...” NCT06671262 ↗ “mFOLFOX6 for 3 cycles - Oxaliplatin 85 mg/m2, 5-fluorouracil 2400mg/m2/46 hours, 5-fluorouracil bolus 400mg/m2 and leucovorin 400 mg/m2, then chemoradiation for 5 cycles -...” NCT03110926 ↗ “This study is an open, single center, exploratory clinical trial aimed at evaluating the safety and efficacy of HRS-4642 in combination with gemcitabine and albumin-bound...” NCT06587061 ↗ “The TS regimen includes paclitaxel at a dose of 175 mg/m² administered via intravenous infusion on Day 1, and oral administration of tegafur-gimeracil-oteracil (S-1) for 14...” NCT07182565 ↗ “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Liposomal Doxorubicin; * Docetaxel; *...” NCT03949283 ↗ “The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection)...” NCT00251095 ↗ “Induction therapy: Albumin-bound paclitaxel 260 mg/m² + cisplatin 75 mg/m² (divided on days 1 - 3) + S1 calculated according to body surface area, taken twice daily (days 1 -...” NCT07085234 ↗ “PD-1 inhibitor plus TP or GP regimen chemotherapy (Paclitaxel or Liposomal Paclitaxel + Carboplatin or Cisplatin , nab-paclitaxel + Carboplatin or Cisplatin, Gemcitabine +...” NCT07337096 ↗ “The TPC regimen included nab-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken...” NCT06669611 ↗ “Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC;...” NCT05940532 ↗ “AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel...” NCT05378334 ↗ “Eligible patients were randomly assigned in a 1:1 ratio to receive ivonescimab or tislelizumab, in combination with paclitaxel and carboplatin for four cycles, followed by...” PMID 42218899 ↗ May 2026 “They will then receive postoperative IPC i.e intravenous and intraperitoneal administration (IV Paclitaxel, 135mg/m2 on D1, IP Carboplatin, AUC 6 on D1, and IP Paclitaxel,...” NCT04282356 ↗ “Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at...” NCT00739830 ↗ “LEP-ETU is a novel, proprietary delivery system of paclitaxel developed by NeoPharm, Inc. Paclitaxel (currently marketed as Taxol) is an anti-microtubular network agent and is...” NCT01190982 ↗ “The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third...” NCT03077243 ↗ “Two hundred twenty-nine chemotherapy-naive patients with advanced-stage NSCLC were enrolled onto a phase II selection trial evaluating sequential or concurrent chemotherapy...” PMID 18612151 ↗ Jul 2008 “platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different...” NCT02891824 ↗ “Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel,...” NCT05383001 ↗ “Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was...” NCT00312728 ↗ “The purpose of this clinical trial is to evaluate the efficacy and safety of Fluzoparib combined with docetaxel in sequential paclitaxel combined with cyclophosphamide for...” NCT07162051 ↗ “Eligible participants with recurrent or metastatic squamous cell carcinoma will receive 4 cycles of carboplatin area under the curve (AUC) 3 IV every 21 days and paclitaxel 135...” NCT06731413 ↗ “Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed...” NCT03921671 ↗ “this study aims to observe and explore the efficacy and safety of the combination of albumin-bound paclitaxel (keaili) and liposomal doxorubicin (duomeisu) in the treatment of...” NCT04859465 ↗ “Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the...” NCT00934895 ↗ “ABI-007 is a new anticancer medication containing the same active ingredient as Taxol, paclitaxel, but formulated as a protein-stabilized material that is suspended in salt...” NCT00046527 ↗ “Platinum-based neoadjuvant chemotherapy (carboplatin at AUC 5 or 6 combined with either paclitaxel at 175 mg/m² or pemetrexed at 500 mg/m²), administered with nivolumab at 0.3...” NCT06667154 ↗ “Drug: Taxane chemotherapy Docetaxel, 75mg/m², D1, Q3W, iv drip, maximum 6 cycles; or paclitaxel, 175mg/m², D1, Q3W, iv drip, maximum 6 cycles; or nab-paclitaxel, 260mg/m², D1,...” NCT07581821 ↗ “After enrollment, patients will receive first-stage treatment consisting of cisplatin plus nanoparticle albumin-bound paclitaxel chemotherapy combined with Aparolitolovureli...” NCT07283991 ↗ “Paclitaxel is given weekly for a period of 12 weeks (weeks 12 to 23) at 80mg/m2 (Dilute with 250 to 500 mL NS or D5W (final concentration of 0.3 to 1.2 mg/mL) and administered...” NCT07102940 ↗ “combined with fluorouracil plus leucovorin, oxaliplatin, and albumin bound paclitaxel (Nab-POF) regimen in the treatment of patients with unresectable locally advanced or...” NCT04510064 ↗ “They were randomly assigned, after stratification by stage, to receive either three cycles of neoadjuvant chemotherapy using paclitaxel and carboplatin once every 3 weeks...” PMID 29432076 ↗ Feb 2018 “Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for...” NCT00563953 ↗ “According to the NCCN Guidelines (2024.V2), the first-line chemotherapy regimen for persistent, recurrent, or metastatic cervical cancer is preferably carboplatin/paclitaxel...” NCT07153952 ↗ “Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus...” NCT00318370 ↗ “Patients with symptomatic femoro-popliteal atherosclerotic disease undergoing percutaneous transluminal angioplasty were randomized to paclitaxel-coated IN.PACT Pacific or...” PMID 23192918 ↗ Nov 2012 “For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and...” NCT05691829 ↗ “The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral...” NCT05383274 ↗ “ABI-007 \[Abraxane™ (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)\] is the first in its class of biologically interactive albumin-bound forms...” NCT00284752 ↗ “Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer...” NCT06278870 ↗ “The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel...” NCT06424899 ↗ “investigator selected chemotherapy regimen (paclitaxel, pemetrexed or gemcitabine and other chemotherapeutic drugs which were not administered in the first-line therapy) for a...” NCT05842018 ↗ “After successful angioplasty (≤30% residual stenosis), lesions were treated with either a paclitaxel-coated balloon or an uncoated control balloon of similar design to the...” PMID 30042225 ↗ Jul 2018 “Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer...” NCT05621434 ↗ “Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are...” NCT03329378 ↗ “There will be six groups: 1) combination with paclitaxel, 2) combination with topotecan, 3) combination with doxorubicin, 4) combination with 5-fluorouracil, folinic acid, and...” NCT06840886 ↗ “The treatment regimen includes the administration of Camrelizumab at a dose of 200 mg, Paclitaxel (albumin-bound) at 260 mg/m², and Carboplatin with an area under the curve (AUC) of 5.” NCT07505186 ↗ “Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.” NCT05684731 ↗ “Drugs used in chemotherapy, such as gemcitabine and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.” NCT00100789 ↗ “Participants will receive selected SoC regimen (fulvestrant, paclitaxel + bevacizumab, pegylated liposomal doxorubicin, or capecitabine) administered as specified in the treatment arm.” NCT05985655 ↗ “All eligible patients will receive stage I (low-dose) regimen: paclitaxel, 50 mg/m2 1-hour iv infusion on days 1, 8 and 15, and cisplatin, 40 mg/m2 24-hour iv infusion on days 1 and 8.” NCT00270569 ↗ “One of the following Treatment of Physician Choice will be administered per standard of care: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel” NCT01492101 ↗ “Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist.” NCT04905316 ↗ “Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.” NCT06752382 ↗ “Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks.” PMID 22663011 ↗ Jun 2012 “radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W” NCT06468644 ↗ “Chemotherapy will consist of: * four triweekly cycles of doxorubicin 60 mg/mq plus cyclophosphamide 600 mg/mq, followed by * twelve consecutive cycles of weekly paclitaxel 80 mg/mq” NCT04248998 ↗ “Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.” NCT06727617 ↗ “cisplatin + paclitaxel/ albumin-bound paclitaxel/ gemcitabine/ Pemetroxel+ Toripalimab (cisplatin 75mg/m2 (D1), paclitaxel 175mg/m2 (D1), or albumin-bound paclitaxel 260mg/m2 (D1)” NCT04606303 ↗ “Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.” NCT04293393 ↗ “six 3-weekly cycles of intravenous paclitaxel [175 mg/m2] or docetaxel [75 mg/m2] combined with intravenous carboplatin [area under the curve of 5 mg/mL per min]; surgery group)” PMID 33705695 ↗ Mar 2021 “Cisplatin, 80 mg/m2 and Paclitaxel, 175 mg/m2 on DAY2, Q3W Or Cisplatin, 80 mg/m2 on DAY1 and 5-fluorouracil, 800 mg/m2 on DAYS1-5, Q3W for two cycles. All given intravenously.” NCT05213312 ↗ “Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗ “Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin.” NCT06718309 ↗ “Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.” NCT03180177 ↗ “Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.” NCT03373058 ↗ “Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;” NCT06231680 ↗ “adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)” NCT05286957 ↗ “Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.” NCT01475331 ↗ “A Prospective, Multicenter, Single-Arm Study of AK112 in Combination With Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Treatment for Triple-Negative Breast Cancer” NCT07103447 ↗ “After 3 weeks Iparomlimab and Tuvonralimab (50 mg/2 mL) on day 1 Albumin-bound paclitaxel 125 mg/m² on days 2 and 9 Gemcitabine 1000 mg/m² on days 2 and 9 Apatinib 250 mg qd” NCT07333287 ↗ “Carboplatin AUC 5 or 6 and paclitaxel will be administered at a dose of 175 mg/m2 Q3W, or carboplatin AUC 5 or 6 and paclitaxel 175 mg/m2 Q3W followed by chemoradiotherapy.” NCT07022483 ↗ “TSN1611 BID, Paclitaxel (albumin-bound) at 125 mg/m² and gemcitabine at 1000 mg/m² will be administered via intravenous infusion on Days 1, 8, and 15 of each 4-week cycle.” NCT06385925 ↗ “PCT regimens will include both carboplatin or cisplatin plus pemetrexed (for non-squamous histology) or paclitaxel (for squamous histology) in combination with cemiplimab.” NCT07274384 ↗ “Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine.” NCT02282020 ↗ “The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.” NCT07103395 ↗ “Preoperative therapy will either be FLOT for 8 weeks OR concurrent radiation and chemotherapy (carboplatin and paclitaxel or FOLFOX) for 5-6 weeks, per standard of care.” NCT06044311 ↗ “8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.” NCT01830270 ↗ “Carboplatin + choice of non-platinum chemotherapy drug: taxane, paclitaxel, nab-paclitaxel, gemcitabine or doxorubicin pegylated liposomal with or without bevacizumab.” NCT02759588 ↗ “Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.” NCT06607926 ↗ “The chemotherapy regimen is AC-T: epirubicin 100mg/m2, cyclophosphamide 600mg/m2, every 3 weeks for 4 cycles; followed by paclitaxel 80mg/m2, every week for 12 cycles.” NCT07197697 ↗ “All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks.” NCT03611985 ↗ “The neoadjuvant regimen prior to radiotherapy consists of paclitaxel 135-175 mg/m², cisplatin 75 mg/m², and Sintilimab 200 mg, administered every 3 weeks for 2 cycles.” NCT06916117 ↗ “The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks.” NCT06734702 ↗ “or paclitaxel, 200 mg/m\^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (\*) minute (min) on Day 1 of Cycles 1 through 4 or 6.” NCT00531960 ↗ “A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period.” NCT03788226 ↗ “Each treatment cycle is administered every 21-28 days and consists of chemotherapy (paclitaxel 175 mg/m², cisplatin 75-80 mg/m²) combined with camrelizumab (200 mg).” PMID 42471761 ↗ Jul 2026 “Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.” NCT04585477 ↗ “Chemotherapy will consist of weekly administration of paclitaxel (albumin-bound) 50 mg/m² and carboplatin (AUC=2) for five weeks, given on the days of radiotherapy.” NCT06509568 ↗ “standard of care neoadjuvant chemotherapy with doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles and paclitaxel (80 mg/m2) weekly for 12 cycles.” NCT04677816 ↗ “Study procedures will consist to determinate the tolerated dose of chemotherapy (Carboplatin, paclitaxel) and of radiotherapy (41.4-45 and 50.4 Gy) in the phase I.” PMID 28705182 ↗ Jul 2017 “Intravenous albumin paclitaxel (260 mg/m 2 ), cisplatin (75 mg/m 2 ), and toripalimab (240 mg) were given in sequence on day 1 of each 21 day cycle for two cycles” PMID 37288582 ↗ Aug 2023 “Nanoparticle albumin-bound (nab)-paclitaxel has better efficacy, safety profiles, and no need to use prophylactic steroids compared with solvent-based paclitaxel.” PMID 30348118 ↗ Oct 2018 “Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).” NCT03663166 ↗ “All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg).” NCT06139419 ↗ “Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;” NCT04681287 ↗ “Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label” NCT05256745 ↗ “chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator” NCT01850147 ↗ “The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered” NCT04605913 ↗ “Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.” NCT06276933 ↗ “PD-1 inhibitor combined with chemotherapy (Paclitaxel or Albumin-bound paclitaxel plus Cisplatin or Carboplatin), administered once every 3 weeks for 2 cycles.” NCT07519486 ↗ “Ivonescimab will be administered in combination with paclitaxel (175 mg/m², intravenous infusion) or albumin-bound paclitaxel (260 mg/m², intravenous infusion)” NCT07244965 ↗ “Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.” NCT05524389 ↗ “We investigated the use of paclitaxel-coated angioplasty balloons and paclitaxel dissolved in the angiographic contrast medium during angioplasty of the leg.” PMID 18272892 ↗ Feb 2008 “This albumin-bound nanoparticle form of paclitaxel increases tumor accumulation of paclitaxel though binding of albumin to SPARC in pancreatic cancer stroma.” NCT01744353 ↗ “Ivonescimab(20mg/kg) combined with paclitaxel polymeric micelles (≤300mg/㎡) and platinum(cisplatin 75mg/㎡or carboplatin AUC5) IV every 3 weeks for 4 cycles.” NCT07009925 ↗ “paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.” NCT06775275 ↗ “chemotherapy: Starting from the first week of radiotherapy and chemotherapy, cisplatin 40mg/m2 and paclitaxel 35mg/m2 were given intravenously for 30-60min” NCT05437692 ↗ “Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle)” NCT03410693 ↗ “Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.” NCT01698281 ↗ “INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)” NCT06477692 ↗ “albumin-bound paclitaxel for injection Paclitaxel for injection (albumin-bound type) dose: 3 dose groups (di=260 mg/m2, di-1=220 mg/m2, di-2=180 mg/m2).” NCT04602013 ↗ “Patients were treated with albumin-bound paclitaxel 100 mg/m2 and carboplatin at area under the curve (AUC) = 2 on days 1, 8, and 15 of a 28-day cycle.” PMID 20705560 ↗ Aug 2010 “To evaluate the efficacy and safety Genexol-PM(CrEL-free polymeric micelle formulated paclitaxel)and gemcitabine in untreated metastatic NSCLC patients” NCT01770795 ↗ “Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI” NCT00790816 ↗ “Squamous NSCLC: nanoparticle albumin-bound paclitaxel 260 mg/m² IV over 30 min and carboplatin AUC 5 IV over 120 min or per institutional standard.” NCT07410975 ↗ “The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).” NCT04121039 ↗ “The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).” NCT03788174 ↗ “The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).” NCT03244774 ↗ “Induction intravenous docetaxel every 3 weeks or paclitaxel every week could be administered for 18 to 24 weeks at the investigator's discretion” PMID 30106636 ↗ Aug 2018 “Patients receive standard induction chemoimmunotherapy (carboplatin, paclitaxel, and pembrolizumab) in three 21-day cycles, beginning on Day 1.” NCT07335380 ↗ “Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.” NCT04031885 ↗ “Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.” NCT04016389 ↗ “Patients will first receive two cycles of neoadjuvant therapy consisting of albumin-bound paclitaxel, cisplatin, toripalimab, and surufatinib.” NCT07086469 ↗ “Pelareorep at 1.5×10\^10 TCID50, 3×10\^10 TCID50, 4.5×10\^10 TCID50 on Day 1/2/8/9/15/16 with Paclitaxel at 80 mg/m\^2 on Day 1/8/15 per cycle” NCT05519059 ↗ “Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine” NCT06301165 ↗ “Abraxane, an albumin-bound formulation of paclitaxel has shown significant single-agent activity in breast cancer and in head and neck cancer.” NCT00319839 ↗ “Paclitaxel plus Carboplatin (TC) therapy; Paclitaxel (PTX) 175 mg/m2 + Carboplatin(CBDCA) area under curve(AUC) 6 q3weeks day1, 3 to 6 cycles” NCT04063527 ↗ “Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)” NCT02580253 ↗ “chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles” NCT05691010 ↗ “Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS).” NCT04776447 ↗ “Non-squamous carcinoma: pemetrexed + platinum or paclitaxel + platinum Squamous carcinoma: paclitaxel + platinum or gemcitabine + platinum” NCT05798845 ↗ “paclitaxel for Injection 175 mg/m2,IV, d1/paclitaxel for Injection (Albumin Bound) 260mg/m2,IV, d1, q3w +carboplatin AUC 4-6,IV, d12,q3w” NCT04471480 ↗ “Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.” NCT02970539 ↗ “Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.” NCT02681432 ↗ “The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d.” NCT06093438 ↗ “Chemotherapy (carboplatin + paclitaxel) will be administred by intravenous infusion, AUC 5-6 q3w - 5 cycles during the treatment period” NCT05183984 ↗ “Participants will take eparbrutinib (QL1706) alongside cisplatin and albumin-bound paclitaxel (TC) every three weeks for three cycles.” NCT07205497 ↗ “Cadonilimab (10 mg/kg, IV, every 6 weeks, D2) and Ivonescimab (20 mg/kg, IV, every 3 weeks, D1) plus paclitaxel \[260 mg/m2, IV, D1\].” NCT06620796 ↗ “Patients with lung squamous cell carcinoma receive albumin-bound paclitaxel, and patients with lung adenocarcinoma receive pemetrexed.” NCT07561983 ↗ “Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.” PMID 42368972 ↗ Jun 2026 “Paclitaxel 175 milligrams per meter square (mg/m\^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21 day cycles” NCT00191646 ↗ “nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) 100 mg/m² on Days 1 and 8 (D1/D8), intravenous infusion, every 3 weeks (Q3W);” NCT07437898 ↗ “First-line chemotherapy regimen: gemcitabine combined with albumin-bound paclitaxel or FOLFIRINOX; second-line chemotherapy regimen:” NCT04677192 ↗ “Patients also receive paclitaxel albumin-bound nanoparticle formulation IV over 30 minutes on days 1, 8 ,15, 22, 29, 36, 43, and 50.” NCT00654836 ↗ “Docetaxel（75 mg/m² ）or paclitaxel（175 mg/mg） plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks)” NCT07063329 ↗ “Paclitaxel: Given intravenously on Days 1, 8, 15, and 22 of each 4 - week treatment cycle at a dose of 80 mg/m² per administration.” NCT06990503 ↗ “AP chemotherapy regimen was pemetrexed combined with cisplatin, and TP chemotherapy regimen was paclitaxel combined with cisplatin.” NCT05020457 ↗ “TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study” NCT03698825 ↗ “-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .” NCT03577743 ↗ “Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.” NCT01967043 ↗ “Albumin-bound paclitaxel 260mg/m2, IV, q3w, or 100-125mg/m2, IV, days 1, 8, and 15, q4w OR Liposomal paclitaxel 175mg/m2, IV, q3w” NCT06102824 ↗ “Standard taxane (docetaxel 75 mg/m\^2 IV every 3 weeks or paclitaxel 80 mg/m\^2) IV once a week according to investigator choice.” NCT01641939 ↗ “The possible choices as defined by the protocol: * Paclitaxel * Gemcitabine * Pegylated liposomal doxorubicin (PLD) * Topotecan” NCT07546500 ↗ “All patients will receive two cycles of induction therapy with albumin-bound paclitaxel and cisplatin combined with toripalimab.” NCT06912074 ↗ “physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care” NCT02067416 ↗ “Pemetrexed (500mg/m2)/Paclitaxel (260mg/m2) Carboplatin (AUC=4-5) Atezolizumab(1200mg) ivgtt, every 21 days Range from 4 cycles” NCT05295212 ↗ “Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);” NCT01167049 ↗ “4 cycles (Doxorubicin+Cyclophosphamide) followed by 12 cycles Paclitaxel+ Metformin (1000 mg twice daily) followed by surgery.” NCT04559308 ↗ “The GnP regimen is a standard-of-care chemotherapy consisting of Gemcitabine and nab-Paclitaxel administered in 21-day cycles.” NCT07336953 ↗ “Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care” NCT03088059 ↗ “Patients received neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2, day 1 and 8 of each 21-day cycle, intravenous)” PMID 41713473 ↗ Feb 2026 “received intravenous paclitaxel (135 mg/m²) and carboplatin (AUC=2-5) on day 1, administered every three weeks for two cycles” NCT06775652 ↗ “chemotherapy protocol consisted of albumin-bound paclitaxel (260mg/m2, with a maximum dose of 400mg) + carboplatin (AUC = 5).” NCT07385664 ↗ “(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)” NCT02688803 ↗ “Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28” NCT03353831 ↗ “All patients will receive three cycles of paclitaxel and carboplatin chemotherapy combined with PD-1/PD-L1 inhibitor therapy” NCT07003620 ↗ “NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)” NCT03188991 ↗ “Participants receive QL1706 every 3 weeks (Q3W) + Albumin-bound paclitaxel every 3 weeks (Q3W) + Cisplatin (Q3W) x 4 cycles.” NCT07372079 ↗ “Squamous cell carcinoma: Serplulimab: 4.5mg/kg, i.v, day1; albumin paclitaxel 260mg/m2, day1; carboplatin AUC=5, i.v, day1.” NCT05882513 ↗ “all patients will also receive treatment with carboplatin and either gemcitabine or paclitaxel for a maximum of 6 cycles” NCT00700180 ↗ “The chemotherapeutic agents include Doxorubicin, Gemcitabine , Paclitaxel, 5 Fluorouracil , Oxaliplatin, and Irinotecan.” NCT07254091 ↗ “and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.” NCT00669565 ↗ “Paclitaxel and cisplatin are well-recognized for their activity in treating a variety of tumors including breast cancer.” NCT01207102 ↗ “Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course.” NCT02511847 ↗ “Gemcitabine (200mg/l), carboplatin (100mg/l) and paclitaxel (20mg/l) will be each diluted in each in 160ml of NaCl0.9%.” NCT05835804 ↗ “Paclitaxel 80mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.” NCT05843292 ↗ “Chemotherapy regimen: Paclitaxel (150 mg/m²) intravenously on Day 1 and Carboplatin (400 mg/m²) intravenously on Day 2.” NCT07115095 ↗ “paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)” NCT02789332 ↗ “HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules” NCT04993040 ↗ “neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab” NCT01340430 ↗ “The choice of chemotherapy plus immunotherapy for squamous cell carcinoma is gemcitabine or paclitaxel or vinorelbine.” NCT06032052 ↗ “Head-to-Head Comparison of SIROlimus Versus Paclitaxel Drug-Eluting BallooN Angioplasty in the Femoropopliteal Artery” NCT04475783 ↗ “All participants will receive three 21-day cycles of carboplatin, paclitaxel, and pembrolizumab as induction therapy.” NCT07428148 ↗ “Chemotherapy: paclitaxel 50mg/ m2 + cisplatin 25mg/ m2, intravenous infusion of day1, once a week, a total of 5 times” NCT06885814 ↗ “The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea.” NCT02923193 ↗ “Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).” NCT03963882 ↗ “Paclitaxel is poorly absorbed orally; encequidar (E), a novel P-glycoprotein pump inhibitor, allows oral absorption.” PMID 35858154 ↗ Jul 2022 “Patients are going to receive weekly chemotherapy (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]).” NCT03254511 ↗ “Patients will undergo intraperitoneal chemotherapy with Paclitaxel (4 cycles) associated with systemic chemotherapy.” NCT05541146 ↗ “DHP107, an oral paclitaxel with a novel lipid formulation designed to be systemically absorbed without Cremophor EL” PMID 42215716 ↗ May 2026 “ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.” NCT00995488 ↗ “paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.” NCT03904927 ↗ “Paclitaxel (albumin-bound) : paclitaxel, 175mg/m2, given intravenously every 3 weeks for 8 cycles (period 21 days).” NCT05241132 ↗ “IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles” NCT00919984 ↗ “Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique.” NCT03304210 ↗ “Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity” NCT01155505 ↗ “Single-agent or combination chemotherapy regimens include dacarbazine, temozolomide, paclitaxel, and carboplatin.” NCT07406724 ↗ “Albumin-bound Paclitaxel: 100 mg/m², administered intravenously on Days 1 and 8, once every 3 weeks, for 6 cycles” NCT07105592 ↗ “TC : paclitaxel 135mg/m2, or nab-paclitaxel paclitaxel 180mg/m2, d1, iv, carboplatin AUC=5, d1, iv, q3w，2 cycles.” NCT07112833 ↗ “The 130-nm albumin-bound formulation of paclitaxel ([Abraxane, ABX ];Celgene,Summit,NJ) is a promising new agent” NCT01735409 ↗ “Paclitaxel 60-80 mg/m2 + carboplatin area under curve (AUC) 2-2.7 d 1, 8, 15 every 3 or 4 weeks (Q3W or Q4W);” NCT04055038 ↗ “Gemcitabine (1000mg/m2，d1, 8) + albumin-bound paclitaxel (125mg/m2，d1, 8) , repeat every 3 weeks for 6 cycles” NCT04699539 ↗ “Patients receive cisplatin intravenously (IV) over 1 hour and paclitaxel IV over 1 hour on days 1, 8, and 15.” NCT00680758 ↗ “PG consists of Paclitaxel 80 mg/m2 iv in day 1 and day 15 and Gemcitabine 1000 mg/m2 iv in day 1 and day 15.” NCT03674424 ↗ “50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel” NCT02398747 ↗ “albumin-bound paclitaxel 260mg/m2, carboplatin AUC=5 and adebrelimab 1200mg were administered intravenously.” NCT07137858 ↗ “Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.” NCT03955367 ↗ “Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously)” NCT02095782 ↗ “14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5” NCT01669226 ↗ “Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.” NCT04201561 ↗ “Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15.” NCT03799692 ↗ “Concurrent Chemotherapy consists of weekly albumin-bound paclitaxel 50mg/m2, d1 plus cisplatin 25mg/m2，d1.” NCT06545747 ↗ “Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD” NCT01619111 ↗ “Two cycles of Paclitaxel 200 mg/m2, Carboplatin AUC 6 and Durvalumab 1500 mg intravenously every 21 days.” NCT04230408 ↗ “A taxane-based chemotherapeutic agent (e.g., paclitaxel or docetaxel) will be administered intravenously.” NCT06843681 ↗ “Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg” NCT01782339 ↗ “with intraperitoneal paclitaxel and cisplatin, and oral S-1 in gastric cancer with peritoneal metastasis.” NCT02995850 ↗ “T: docetaxel, nab-paclitaxel or paclitaxel. Routine clinical dosage and administration shall be adopted.” NCT07410234 ↗ “chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion” NCT03067610 ↗ “Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle.” NCT03957564 ↗ “Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets” NCT04168957 ↗ “Chemotherapy options include: carboplatin or cisplatin along with pemetrexed, paclitaxel or gemcitabine” NCT06800339 ↗ “Optilume is a CE-marked paclitaxel-coated dilatation balloon used for treatment of urethral strictures.” NCT06795074 ↗ “pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.” NCT03322566 ↗ “Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.” NCT04995120 ↗ “4 adjuvant cycles carboplatin and paclitaxel followed by External beam pelvic radiotherapy (45-50 Gy )” NCT05179447 ↗ “Toripalimab 240mg, Carboplatin AUC5+ paclitaxel 200 mg/m ², iv, 3 weeks per cycle, 2-4 cycles in total” NCT04716751 ↗ “Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer” NCT02072317 ↗ “Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks.” NCT06611813 ↗ “Patients will start with induction chemotherapy of carboplatin, paclitaxel and cetuximab for 6 weeks” NCT06984861 ↗ “Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks.” NCT06977893 ↗ “Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)” NCT03329690 ↗ “Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.” NCT06771154 ↗ “monotherapy chemotherapy (paclitaxel 175mg/m2 or docetaxel 75mg/m2 or irinotecan 270mg/m2, d1, q3w)” NCT07016737 ↗ “Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles” NCT02441933 ↗ “Paclitaxel, administered intravenously at a dose of 260 mg/m2 every 3 weeks for a total of 12 weeks” NCT07383818 ↗ “Carboplatin + paclitaxel + pembrolizumab followed by doxorubicin + cyclophosphamide + pembrolizumab” NCT06535893 ↗ “Chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide per standard of care.” NCT03745222 ↗ “a combination of two drugs administered intravenously: Paclitaxel and Carboplatin (CarboP-pacliT).” NCT02359968 ↗ “inupadenant in combination with chemotherapy SOC carboplatin and paclitaxel in patients with TNBC” NCT03873883 ↗ “Paclitaxel:175mg/ m2, administered intravenously every three weeks on the first day of each cycle” NCT05448781 ↗ “Paclitaxel (albumin-bound) for injection: 260 mg/m², administered intravenously over 30 minutes.” NCT06866951 ↗ “Paclitaxel-Coated Balloon for the Treatment of Symptomatic Recurrent Benign Intestinal Stricture” NCT03886324 ↗ “BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2” NCT01085136 ↗ “single agent immunotherapy with Pembrolizumab or in combination with Carboplatin or Paclitaxel” NCT05222087 ↗ “TI: Paclitaxel 200mg/m² on day 1, Ifosfamide 2000mg/m² daily from days 1 to 3 of 14-day cycle.” NCT06418789 ↗ “Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets” NCT03588039 ↗ “Paclitaxel for Injection (Albumin-bound): 125 mg/m² on Days 1 and 8, every 3 weeks per cycle.” NCT07240766 ↗ “Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle.” NCT03833466 ↗ “Paclitaxel is a novel broad-spectrum antitumor drug,which has a unique anti-cancer mechanism.” NCT03604614 ↗ “Albumin paclitaxel 125 mg / m2, D1, D8 + cisplatin 75 mg / m2, D1, every 3 weeks for 1 cycle” NCT05381636 ↗ “Abraxane is a new preparation of the active ingredient in the chemotherapy drug, paclitaxel.” NCT00454324 ↗ “(Note: Gemcitabine can be replaced by docetaxel, albumin-bound paclitaxel, paclitaxel, etc.)” NCT07328854 ↗ “Tislelizumab 200 mg iv D1, Paclitaxel 175 mg/m2 iv D1, and Carboplatin AUC 5 mg/mL/min iv D1” NCT06914011 ↗ “Genexol-PM is a novel Cremophor® EL (CrEL)-free polymeric micelle formulation of paclitaxel.” PMID 22012004 ↗ Oct 2011 “PCC protocol (Paclitaxel - Carboplatin - Cetuximab) by intravenous injection for 16 cycles.” NCT06725368 ↗ “Bevacizumab as MYL-1402O 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV” NCT04633564 ↗ “* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy.” NCT04900623 ↗ “All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)” NCT06703047 ↗ “Recommended chemotherapy regimen: liposome paclitaxel 135mg/m2 d1 +DDP 25 mg/m2 D1-3, Q21.” NCT05872724 ↗ “Bevacizumab was combined with docetaxel in 90% of Chinese patients and paclitaxel in 10%.” PMID 22490570 ↗ Mar 2012 “Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin” NCT05775796 ↗ “or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.” NCT05787613 ↗ “Albumin-bound paclitaxel: intravenous infusion, 50mg/m2, D1, QW, for 5 consecutive doses.” NCT06888531 ↗ “For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days” NCT03651206 ↗ “Cycles 1-4: Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle.” NCT06639672 ↗ “30 mg / m2 albumin bound paclitaxel was intravenously infused twice a week for 0.5 hours” NCT04524299 ↗ “Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W” NCT05574998 ↗ “Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis” NCT07191860 ↗ “either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa” NCT03657966 ↗ “cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC” NCT05583188 ↗ “pemetrexed + carbo/cis or paclitaxel + carbo or docetaxel + carbo/cis for non squamous” NCT06003075 ↗ “Neoadjuvant Chemotherapy with paclitaxel (or albumin - bound paclitaxel) and cisplatin” NCT06957938 ↗ “Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion” NCT04784715 ↗ “Paclitaxel/Platinum(Carboplatin+Cisplatin+Paclitaxel)administered intravenously (IV).” NCT02327078 ↗ “Finally the investigators assess the efficacy and safety of Albumin-bound Paclitaxel.” NCT01647672 ↗ “Albumin-bound paclitaxel: 125 mg/m2, i.v., on Day 1 and Day 8 of each treatment cycle” NCT06573398 ↗ “Paclitaxel (135 mg /m2) and carboplatin (AUC=5) every 3 weeks for two cycles (D1,D22)” NCT05424432 ↗ “systemic intravenous chemotherapy using carboplatin and paclitaxel at standard doses” NCT04811703 ↗ “Serplulimab (300mg) + Albumin-bound paclitaxel + Cisplatin/Carboplatin, Q3W, 3cycles” NCT07403435 ↗ “ABI-007 (brand name Abraxane™) is a form of the chemotherapy drug called paclitaxel.” NCT00585689 ↗ “Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel” NCT04667793 ↗ “Carboplatin + Paclitaxel administered at each cycle of 21 days (in total 3 cycles).” NCT07637851 ↗ “Paclitaxel injection: 30 mg (5 mL) per vial; 175 mg/m² intravenously every 3 weeks” NCT07492342 ↗ “Genexol-PM is a polymeric micellar formulation of paclitaxel without Cremophor EL.” PMID 30796155 ↗ Feb 2019 “Chemotherapy : paclitaxel and carboplatin, followed by epirubicin-cyclophosphamide” NCT06977542 ↗ “B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.” NCT06339060 ↗ “Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest” NCT00281697 ↗ “Could be paclitaxel, docetaxel or Nab-paclitaxel, according to physician's choice.” NCT07317778 ↗ “80 mg/m2 paclitaxel every week for 12 weeks (carboplatin-paclitaxel intravenously)” PMID 42372741 ↗ Jul 2026 “pemetrexed 500 mg/m² for non-squamous or paclitaxel 175 mg/m² for squamous tumors” NCT07084610 ↗ “Albumin bound paclitaxel, 100 mg/m2, was given intravenously on days 1, 8, and 15” PMID 28114604 ↗ Jul 2017 “Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)” NCT03275506 ↗ “Cisplatin+paclitaxel will be administered once every three weeks for four cycles.” NCT03927495 ↗ “Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules” NCT02730481 ↗ “Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.” NCT03693248 ↗ “HIPEC treatment (paclitaxel, 3000 ml of physiological saline at 43°C for 60 min)” NCT06427252 ↗ “Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization” NCT01042379 ↗ “Albumin-bound paclitaxel 125 mg/m² (days 1 \& 8) plus carboplatin AUC 6 (day 1)” NCT07457359 ↗ “Paclitaxel: Participants will receive 175 mg/ m\^2, day 1 , 21 days/cycle, Q21D” NCT05186506 ↗ “Nedaplatin 25 mg/m2 and Paclitaxel liposome 45mg/m2, day 1, every week, 5 weeks” NCT04275986 ↗ “Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15” NCT02429037 ↗ “Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles” NCT05978193 ↗ “Paclitaxel - Hyaluronic Acid 600 mg - Solution for intravesical administration.” NCT04661826 ↗ “a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen” NCT06523673 ↗ “Albumin-bound Paclitaxel (100mg/m² Q3W D1/D8/D15 or130mg/m²D1/D8 or 260mg/m²D1)” NCT07139041 ↗ “Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin.” NCT03393507 ↗ “Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel” NCT05561127 ↗ “TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W” NCT06478355 ↗ “Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)” NCT02470468 ↗ “DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel” NCT02107937 ↗ “NPC patients receive paclitaxel (175mg/m2) and carboplatin (AUC=5) treatment” NCT01891123 ↗ “Albumin-bound paclitaxel: 260 mg/m², IV, administered on day 1 of each cycle” NCT06627712 ↗ “IPH5301 will be administrated in combination with trastuzumab and paclitaxel” NCT05143970 ↗ “Cisplatin/carboplatin + albumin-bound paclitaxel/paclitaxel (squamous NSCLC)” NCT06939127 ↗ “oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets” NCT03544567 ↗ “Taxane (Paclitaxel) weekly on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78” NCT02685306 ↗ “Carboplatin AUC 6 iv day 1 and paclitaxel 200 mg/mq iv day 1 every 21 days.” NCT03823625 ↗ “Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)” NCT01849874 ↗ “Albumin-bound Paclitaxel 260 mg/m² on Day 1, every 3 weeks (Q3W) × 4 cycles” NCT06908668 ↗ “paclitaxel was given 150 mg/m\^2 i.v. on day 1, every 21 days for 2 cycles.” NCT04181372 ↗ “Albumin-bound Paclitaxel: 260mg/m², IV infusion, Day 1 (21 days per cycle)” NCT06848439 ↗ “Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days” NCT02866370 ↗ “Squamous: Carboplatin AUC 5 + Gemcitabine 1000mg/m2 or Paclitaxel 200mg/m2” NCT04728724 ↗ “(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6” NCT00437749 ↗ “plus paclitaxel (80 mg per square meter of body-surface area once weekly)” NCT06831955 ↗ “Drug: Paclitaxel 135-175 mg/m2 on Day 1 of each 3-week cycle for 2 cycles” NCT06354530 ↗ “Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks” NCT03899610 ↗ “Ivonescimab 20mg/kg + chemotherapy (Cisplatin + Paclitaxel) Q3W, 3 cycles” NCT06814158 ↗ “Subsequent Taxol cycles (Paclitaxel 80mg/m2 IV) once weekly for 12 weeks.” NCT04170465 ↗ “The preferred concurrent chemoradiation is carboplatin/paclitaxel weekly.” NCT06906887 ↗ “The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2)” NCT03707639 ↗ “Chemotherapy regimen: Paclitaxel: 135 mg/m², Day 1, every 3 weeks (Q3W);” NCT07015489 ↗ “Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.” NCT03892018 ↗ “The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2)” NCT04174339 ↗ “A. T: Paclitaxel 50 mg/m2, 1h IVF, weekly, week 1 to week 5 during CRT.” NCT03623737 ↗ “Lutonix is a paclitaxel coated balloon which delivers the drug locally.” NCT02632955 ↗ “From Days 2-3, patients underwent paclitaxel + carboplatin chemotherapy” NCT07068178 ↗ “nab-paclitaxel paclitaxel 180mg/m2, or paclitaxel 135-175mg/m2, d1, iv;” NCT06420908 ↗ “Paclitaxel (P): Paclitaxel will be administered at the dose of 80 mg/m2” NCT01455532 ↗ “Chemotherapy list: * Liposomal Doxorubicin; * Docetaxel; * Paclitaxel;” NCT03632798 ↗ “Paclitaxel (90 mg/m2)on day 1 and 8 Cisplatin (40 mg/m2)on day 1 and 8.” NCT00452803 ↗ “Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel” NCT06010303 ↗ “investigator-selected taxane (docetaxel, paclitaxel, or nab-paclitaxel)” PMID 41576297 ↗ Jan 2026 “Paclitaxel, 175mg/m2 or albumin paclitaxel, 260mg/m2, iv. drip, D1, Q3W” NCT06750952 ↗ “Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks” NCT04188847 ↗ “four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).” NCT01066234 ↗ “Cisplatin, pemetrexed, gemcitabine, carboplatin, paclitaxel, docetaxel” NCT06623656 ↗ “chemotherapy：paclitaxel liposomes 50mg / m2, ivgtt, d8, 15, 22, 29, 36” NCT04164797 ↗ “May include carboplatin with gemcitabine, or paclitaxel or pemetrexed” NCT04966676 ↗ “Paclitaxel: paclitaxel 80 mg/m2 ivgtt d1, d8, d15, 28 days per cycle.” NCT04215003 ↗ “Albumin-bound paclitaxel (ab-P) was safe and more effective than cf-P” PMID 21976055 ↗ Oct 2011 “(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel” NCT02483767 ↗ “paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle)” NCT03986528 ↗ “3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2” NCT03815903 ↗ “Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks.” NCT01426880 ↗ “Paclitaxel: 150-175 mg/m², intravenous infusion, every 3 weeks (Q3W).” NCT07033819 ↗ “non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin” NCT06136910 ↗ “Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles.” NCT05343325 ↗ “Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2” NCT00140075 ↗ “e.g., paclitaxel 80 mg/m² weekly or docetaxel 75-100 mg/m² triweekly” NCT06970912 ↗ “Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days” NCT00476216 ↗ “3 cycles carboplatin + paclitaxel maintenance therapy with niraparib” NCT05460000 ↗ “weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)” NCT06730308 ↗ “Albumin-bound paclitaxel over 30 minutes IV followed by Gemcitabine” NCT01964287 ↗ “Albumin-binding paclitaxel: 260 mg/m 2 Q3W, IV, for 30 min + 5 min.” NCT06509971 ↗ “Paclitaxel is one of the most widely used human anticancer agents.” NCT00989131 ↗ “Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2” NCT00070629 ↗ “Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin” NCT06732323 ↗ “Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles” NCT04280822 ↗ “Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion” NCT03945227 ↗ “Paclitaxel or Paclitaxel liposome 135-175mg/m2 D1 IV Q3W(Squamous）” NCT07138755 ↗ “Combination chemotherapy (pemetrexed, paclitaxel, or carboplatin).” NCT07111520 ↗ “Albumin-bound paclitaxel: 125 mg/m², day 1 and day 8, 21-day cycle” NCT07342283 ↗ “drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)” NCT01495533 ↗ “Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.” NCT06264180 ↗ “EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2)” NCT01537536 ↗ “paclitaxel-platinum combination is favoured in squamous carcinoma” NCT06840782 ↗ “Weekly carboplatin and paclitaxel at standard doses is preferred.” NCT03234842 ↗ “followed by weekly paclitaxel, dose-dense paclitaxel or docetaxel” NCT06186700 ↗ “weekly paclitaxel (Taxol((R))) combination chemotherapy with UFT” PMID 16804524 ↗ Jun 2006 “Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.” NCT06091943 ↗ “SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin” NCT05174156 ↗ “Chemotherapy: Paclitaxel 135mg/m2 d1+cisplatin 25mg/m2 d1-3 q28d” NCT06964568 ↗ “Paclitaxel: 175 mg/m2, administered by IV infusion every 3 weeks” NCT04760431 ↗ “teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1” NCT03985670 ↗ “Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle” NCT05512182 ↗ “T: Taxanes, including docetaxel, nab-paclitaxel, and paclitaxel.” NCT07378306 ↗ “High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC” NCT01180335 ↗ “Paclitaxel 175 mg / m2 was given on the first day of each cycle” NCT04950400 ↗ “pemetrexed/paclitaxel/nab-paclitaxel plus carboplatin/cisplatin” NCT07603661 ↗ “Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90” NCT00661739 ↗ “GM102 escalating doses combined with paclitaxel and carboplatin” NCT02978755 ↗ “Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed” NCT03774732 ↗ “Either docetaxel 75 mg/m² or paclitaxel 135-175 mg/m² on day 1” NCT07546383 ↗ “Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy” NCT05742607 ↗ “neoadjuvant ivonescimab combined with paclitaxel and cisplatin” NCT07130240 ↗ “* Paclitaxel: According to 135-175mg/m2, intravenous infusion” NCT05214222 ↗ “Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks” NCT05245760 ↗ “Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22)” NCT01200212 ↗ “and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks)” NCT06336954 ↗ “albumin-bound paclitaxel 175 mg/m2 intravenously administered” NCT00193206 ↗ “SOC that includes paclitaxel 175 milligrams per square meter” NCT03602859 ↗ “Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)” NCT06135714 ↗ “Paclitaxel 150-175 mg/m2, d1; Cisplatin 60-75mg/ m2，d1；Q3W；” NCT06086457 ↗ “standard-of-care IV carboplatin and IV paclitaxel treatment” NCT03029585 ↗ “Albumin bound paclitaxel 125 mg/m² + Gemcitabine 1000 mg/m²” NCT04570943 ↗ “albumin nanoparticle of paclitaxel 260 mg/m2、 ivdrip，d1，q3w” NCT05101616 ↗ “carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1)” NCT03249142 ↗ “Paclitaxel for injection (albumin bound) (260mg/m2 D1, q3w)” NCT06908382 ↗ “albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine” PMID 24131140 ↗ Oct 2013 “Paclitaxel: dose of 175 mg /㎡, Day 1, every 4 weeks (Q4W).” NCT06475599 ↗ “3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w.” NCT00959387 ↗ “Paclitaxel (175 mg/m2 intravenous infusion on Day 1, Q3W)” NCT07233850 ↗ “plus paclitaxel 150-175 mg/m² intravenously over >3 hours” NCT07446335 ↗ “Cisplatin(75 mg/m2) + albumin-bound paclitaxel(260 mg/m2)” NCT04857164 ↗ “The balloon is coated with a paclitaxel drug (3.5ug/mm2).” NCT05883462 ↗ “Cisplatin, Carboplatin, Docetaxel, Paclitaxel, Pemetrexed” NCT02064491 ↗ “albumin-bound paclitaxel plus trastuzumab and pertuzumab” NCT07239271 ↗ “Outpatient Carboplatin + Paclitaxel Regimen (CP Regimen)” NCT05144698 ↗ “HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated” NCT06213519 ↗ “albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles” NCT05862610 ↗ “taxane regimen containing either paclitaxel given weekly” NCT05074290 ↗ “Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks” NCT01669239 ↗ “paclitaxel 175 mg/m\^2 on D1+cisplatin 80 mg/m\^2 on D1” NCT00820755 ↗ “Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks)” NCT03699449 ↗ “Cisplatin and gemcitabine or carboplatin and paclitaxel” NCT06333314 ↗ “chemotherapy (paclitaxel/cisplatinum) and brachytherapy” NCT03243825 ↗ “paclitaxel (175 mg/m\^2 by IV on Day 1, every 21 days)” NCT07526792 ↗ “Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w” NCT05243355 ↗ “treatment dosage: cadonilimab 10 mg/kg, paclitaxel 175” NCT06878196 ↗ “cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15” NCT06208033 ↗ “3 cycles of albumin-bound paclitaxel（260 mg/m2 D1 q3w）” NCT07339488 ↗ “Paclitaxel Injection Concentrate for Suspension (PICS)” NCT04332549 ↗ “cisplatin or carboplatin plus docetaxel or paclitaxel” NCT03529279 ↗ “Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle” NCT06099769 ↗ “Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU” NCT02845908 ↗ “Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU” NCT04155671 ↗ “paclitaxel+cisplatin/carboplatin ± bevacizumab+QL1706” NCT07035808 ↗ “Genexol®(Conventional Paclitaxel With Cremorphor EL)” NCT00876486 ↗ “paclitaxel 175mg/m 2 d1, carboplatin AUC=5 d1 IV Q3W” NCT05183958 ↗ “Albumin-bound paclitaxel:100-150 mg/m², d1, d8, Q3W;” NCT07290010 ↗ “domestic injection paclitaxel (albumin binding type)” NCT03977077 ↗ “Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles” NCT04520035 ↗ “CB-839 in combination with standard dose paclitaxel” NCT02071862 ↗ “docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1” NCT01150513 ↗ “Cycles 1-4: Paclitaxel q1W + Carboplatin q1W or q3W” NCT06358573 ↗ “Chemotherapy Period Paclitaxel Carboplatin Avelumab” NCT03642132 ↗ “OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles” NCT02651610 ↗ “Drug: Cisplatinum Drug: Paclitaxel Drug: Sintilimab” NCT05476965 ↗ “Albumin-bound paclitaxel: 100 mg/m² by IV infusion” NCT06978829 ↗ “paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d” NCT03917069 ↗ “Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22” NCT03558035 ↗ “Cremophor EL-free polymeric micelle of paclitaxel” NCT00882973 ↗ “Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle” NCT06475755 ↗ “Cremophor EL-free polymeric micelle of paclitaxel” NCT02739529 ↗ “Abraxane® (nanoparticle albumin-bound paclitaxel)” NCT00479674 ↗ “AC-P (4+4) \[Adriamycin + Cytoxan + Paclitaxel\]” NCT02457039 ↗ “Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8” NCT04711824 ↗ “Paclitaxel 80 mg/m2 intravenously on day 1 and 8” NCT03472274 ↗ “Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles” NCT00647218 ↗ “carboplatin AUC2, paclitaxel 45-50 mg 2 per week” NCT04182698 ↗ “Albumin bound paclitaxel: 175-260 mg/m2, d1, q3w” NCT07028918 ↗ “Albumin-bound Paclitaxel for Injection 100 mg/m²” NCT07654530 ↗ “Paclitaxel:175 mg/m2,continuous IV., d1, 24h q3w” NCT05476380 ↗ “Drug: Paclitaxel injection Intravenous Infusion” NCT05179317 ↗ “cisplatin-gemcitabine or carboplatin-paclitaxel” NCT00404703 ↗ “taxane (paclitaxel, nab-paclitaxel or docetaxel” NCT05172518 ↗ “Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX” NCT05171530 ↗ “Paclitaxel 175 mg/m2 or 200 mg/m2 every 3 weeks” NCT05254184 ↗ “Paclitaxel 80mg per square meter, d1,d8,d15 q3w” NCT07393425 ↗ “Cisplatin; Carboplatin; Pemetrexed; Paclitaxel;” NCT07672223 ↗ “paclitaxel+carboplatin or pemetrexed+cisplatin” NCT04255836 ↗ “Paclitaxel 175 mg/m2 IV over 3 hours on Day 1,” NCT05705687 ↗ “TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin” NCT02934828 ↗ “Doxorubicin, Paclitaxel, Carboplatin, Eribulin” NCT05774886 ↗ “175 mg/m\^2 paclitaxel by intravenous infusion” NCT06196736 ↗ “Liporaxel is an oral formulation of paclitaxel” NCT06326346 ↗ “Paclitaxel:IV infusion,80 mg/m2,qw;(1-12 week)” NCT07101614 ↗ “Drug:Paclitaxel 175 mg/m\^2 by IV infusion Q3W” NCT04158440 ↗ “the combination of paclitaxel and capecitabine” NCT05861830 ↗ “docetaxel, cetuximab, methotrexate, paclitaxel” NCT03769506 ↗ “Carboplatin + Paclitaxel Regimen (CP Regimen)” NCT06708455 ↗ “receive carboplatin / paclitaxel chemotherapy” NCT04212377 ↗ “Paclitaxel (175 mg/m2) and Carboplatin (AUC5)” NCT05384366 ↗ “carbplatin, paclitaxel, pemetrexed, cisplatin” NCT05407675 ↗ “Paclitaxel or pegylated liposomal doxorubicin” NCT02728622 ↗ “Taxane (Paclitaxel or Docetaxel) IV infusion.” NCT00849667 ↗ “paclitaxel 135-175 mg/m² + carboplatin AUC 5” NCT07472478 ↗ “Paclitaxel plus platinum-based chemotherapy.” NCT07052669 ↗ “E10A combined with Cisplatin and Paclitaxel” NCT00634595 ↗ “albumin-bound paclitaxel injection (Kealil)” NCT06078670 ↗ “Abraxane, which is a new form of paclitaxel” NCT00308178 ↗ “Paclitaxel: 175mg/m2 every 21 days, IV drip” NCT06375707 ↗ “albumin-bound paclitaxel (200mg/m2, 1d Q3W)” NCT05558722 ↗ “4. Paclitaxel - 175-200 mg/m2 every 3 weeks” NCT00246571 ↗ “Paclitaxel: 175mg/m2 every 21 days, IV drip” NCT06656624 ↗ “Paclitaxel 80 mg/m2 every week for 12 weeks” NCT05296746 ↗ “Albumin Paclitaxel 260mg/m2 ivgtt on Day 1” NCT06394661 ↗ “Paclitaxel 175mg/㎡ by 3h iv infusion day 1” NCT01917578 ↗ “Patients receive paclitaxel IV over 1 hour” NCT00006472 ↗ “Drug: Paclitaxel 60 mg/m2, d1, QW,6cycles” NCT06054906 ↗ “or 12 cycles paclitaxel 80 mg/m2 weekly).” NCT03283384 ↗ “Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29” NCT03087864 ↗ “1. Camrelizumab + Cisplatin + Paclitaxel” NCT07251062 ↗ “paclitaxel (albumin-bound) for injection” NCT07398937 ↗ “Paclitaxel for Injection （Albumin Bound）” NCT05507411 ↗ “Paclitaxel - supplied as 30-mg capsules” NCT03165955 ↗ “combined IP Cisplatin and IV Paclitaxel” NCT00889733 ↗ “Paclitaxel for Injection(Albumin Bound)” NCT07262567 ↗ “cisplatin 75 mg/m2 Paclitaxel 175 mg/m2” NCT01917695 ↗ “paclitaxel, 135-175mg/m2, q3w, 3 cycles” NCT06878222 ↗ “Paclitaxel 135mg/m2, carboplatin AUC=5.” NCT03985046 ↗ “paclitaxel 135\~150 mg/m2, i.v. d1,q3w” NCT05738434 ↗ “Paclitaxel injection: intravenous drip” NCT05416775 ↗ “Nivolumab +Carboplatin AUC+ paclitaxel” NCT05964101 ↗ “paclitaxel (80 mg/m2 on days 1 and 8)” PMID 30413379 ↗ Nov 2018 “given with carboplatin and paclitaxel” NCT03780010 ↗ “nab-paclitaxel 260 mg/m² on Day 1 q3w” NCT06876636 ↗ “carboplatin + paclitaxel chemotherapy” NCT06746116 ↗ “Paclitaxel + cisplatin or carboplatin” NCT07627620 ↗ “Paclitaxel at 175 mg/m2 intravenously” NCT00249964 ↗ “paclitaxel: 50 mg / m2 IV over 1 hour” NCT01404156 ↗ “Paclitaxel, ifosfamide, and cisplatin” NCT02817958 ↗ “IP Paclitaxel 40 mg/m2 every 3 weeks” NCT04797923 ↗ “Paclitaxel 50mg/m2, intravenous drip” NCT05561699 ↗ “Paclitaxel: IV, 175 mg/m², Day1, Q3W” NCT05979818 ↗ “Paclitaxel 135-175mg/m2 over 3 hours” NCT04733820 ↗ “bevacizumab and paclitaxel induction” PMID 42128502 ↗ May 2026 “Liposomal paclitaxel: 150mg/m2, Q3W” NCT06709417 ↗ “Paclitaxel 80 mg/m² IV Days 1 and 8” NCT07053150 ↗ “Paclitaxel:150mg/m2,iv, 3h, at day1” NCT03258034 ↗ “Paclitaxel Protein Bound (Abraxane)” NCT03415854 ↗ “Paclitaxel: 175 mg/m2 in day 1, Q3W” NCT04151810 ↗ “paclitaxel 45 mg/m2 IV over 1 hour” NCT00139633 ↗ “Oxaliplatin, Paclitaxel, Pazopanib” NCT02788201 ↗ “Paclitaxel 175mg/m2 IVF for 2hours” NCT01283204 ↗ “Albumin-bound paclitaxel injection” NCT04680988 ↗ “paclitaxel 175 mg/m² every 3 weeks” NCT05255302 ↗ “4 cycles of carboplatin-paclitaxel” NCT01850303 ↗ “Paclitaxel 175 mg/m² IV on day 1” NCT07092696 ↗ “paclitaxel 175 or 200 mg/m2 i.v.” NCT07715396 ↗ “paclitaxel\[260 mg/m\^2 IV Q3W\]” NCT07039656 ↗ “capsules that contain paclitaxel” NCT04180384 ↗ “IV paclitaxel 175 mg /m2 (day 1)” NCT06902467 ↗ “Paclitaxel: 80mg/m2, d1, qw\*12” NCT02455141 ↗ “TP: paclitaxel 135-175mg/m2,d1+” NCT06190782 ↗ “Taxanes (Paclitaxel, Docetaxel)” NCT02299999 ↗ “Paclitaxel Liposome,135mg/m2,d1” NCT01393080 ↗ “Nilotinib Paclitaxel Pazopanib” NCT02551718 ↗ “Paclitaxel: 175 mg/m², D1, Q3W” NCT07358689 ↗ “Paclitaxel (175 mg/m2, day 1)” NCT01133678 ↗ “Taxol (Paclitaxel Injection)” NCT04889768 ↗ “Paclitaxel (Taxol, Abraxane)” NCT00659269 ↗ “paclitaxel 175 mg/m² IV q3w” NCT07161791 ↗ “Paclitaxel 100mg/ m2/day -3” NCT05831033 ↗ “Paclitaxel 175mg/m2 iv day1” NCT03055312 ↗ “paclitaxel (135-175 mg/m²)” NCT05430906 ↗ “Paclitaxel and Carboplatin” NCT03544736 ↗ “paclitaxel 60mg/m2, ivgtt” NCT06402708 ↗ “Paclitaxel Coated Balloon” NCT05561114 ↗ “paclitaxel 135 mg/m2 i.v.” NCT04885270 ↗ “Carboplatin + Paclitaxel” NCT02659059 ↗ “Paclitaxel: IV infusion” NCT07166094 ↗ “Preop chemo: Paclitaxel” NCT02018458 ↗ “Paclitaxel (200 mg/m2)” NCT00420186 ↗ “Drug:Paclitaxel 175 mg” NCT06437977 ↗ “Paclitaxel 135mg/m2 D2” NCT04389177 ↗ “Paclitaxel 175mg/m2 D1” NCT02621333 ↗ “Paclitaxel 175mg/m2 IV” NCT02263495 ↗ “paclitaxel + platinum” NCT00391586 ↗ “paclitaxel 175 mg/m2” NCT07472153 ↗ “Paclitaxel Injection” NCT04400695 ↗ “Paclitaxel 80 mg/m2” NCT00789581 ↗ “Paclitaxel (1 pat.)” NCT01379482 ↗ “Paclitaxel (Taxol®)” NCT02983045 ↗ “Taxol (Paclitaxel)” NCT02195973 ↗ “taxol (paclitaxel)” NCT00518583 ↗ “8. MYC: Paclitaxel” NCT02101385 ↗ “Paclitaxel 175 mg” NCT05173272 ↗ “Drug: Paclitaxel” NCT07477743 ↗ “Drug: Paclitaxel” NCT06476184 ↗ “Drug: Paclitaxel” NCT03872947 ↗ “Drug: Paclitaxel” NCT00735696 ↗ “Drug: Paclitaxel” NCT00762034 ↗ “Drug: Paclitaxel” NCT06241235 ↗ “Paclitaxel” NCT02685306 ↗ “Paclitaxel” NCT06914011 ↗ “Paclitaxel” NCT05476380 ↗ “paclitaxel” NCT07214779 ↗ “Paclitaxel” NCT03177291 ↗ “Paclitaxel” NCT06846346 ↗ “Paclitaxel” NCT05704985 ↗ “Paclitaxel” NCT01703910 ↗ “Paclitaxel” NCT06371807 ↗ “Paclitaxel” NCT01079481 ↗ |
| Known as | ABI-007 | “Abraxane (nab-paclitaxel, nanoparticle albumin-bound paclitaxel; formerly ABI-007) is a Cremophor® EL-free, albumin-bound form of paclitaxel with a mean particle size of...” NCT01161186 ↗34“ABI-007 \[Abraxane™ (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)\] is the first in its class of biologically interactive albumin-bound forms...” NCT00284752 ↗ “Patients receive oral lapatinib on days 1, 2, 8, 9, 15, and 16 and paclitaxel (albumin-stabilized nanoparticle formulation) (ABI-007; Abraxane™) IV over 30 minutes on days 3,...” NCT00313599 ↗ “Randomized, Crossover, Pharmacokinetic Study Of Paclitaxel (Taxol) And ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle Paclitaxel) In Patients With Advanced Solid Tumors” NCT00095914 ↗ “The 130 nm albumin bound paclitaxel (nab-paclitaxel, ABI-007) delivers more paclitaxel to tumor than conventional paclitaxel without cremophor related toxicities.” PMID 24318901 ↗ Dec 2013 “Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas” NCT00844649 ↗ “A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies” NCT00820768 ↗ “ABI-007 is an albumin-bound formulation of paclitaxel that has demonstrated single-agent activity against metastatic melanoma.” PMID 21472717 ↗ Nov 2010 “This study uses the drugs Abraxane (also called ABI-007) and Vandetanib (also called Zactima and ZD6474).” NCT00667147 ↗ “ABI-007 (brand name Abraxane™) is a form of the chemotherapy drug called paclitaxel.” NCT00585689 ↗ “paclitaxel albumin-stabilized nanoparticle formulation (ABI-007; Abraxane\^®)” NCT00404404 ↗ “paclitaxel (albumin-stabilized Nanoparticle formulation) (ABI-007)” NCT00077246 ↗ “ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel)” NCT00397761 ↗ “Bevacizumab and ABI-007 (Abraxane)” NCT00472693 ↗ |
| Known as | Abraxane | “The objective of this research is to find out what effects (good and bad), the sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX, the standard...” NCT05825066 ↗127“The purpose of this study is to assess the safety and efficacy of nab-paclitaxel (Abraxane) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously...” NCT02504333 ↗ “Abraxane (nab-pac, Celgene) is a novel 130 nm, albumin-bound (nab) nanoparticle formulation of paclitaxel which has noteworthy single-agent activity and a favourable toxicity...” NCT03304210 ↗ “Abraxane is a new agent in pancreatic cancer. This albumin-bound nanoparticle form of paclitaxel increases tumor accumulation of paclitaxel though binding of albumin to SPARC...” NCT01744353 ↗ “The aim of this phase II study is to assess the efficacy and safety of sequentially integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and SBRT in patients with...” NCT03158779 ↗ “ABI-007 \[Abraxane™ (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)\] is the first in its class of biologically interactive albumin-bound forms...” NCT00284752 ↗ “TT-00420 tablet in combination with nab-paclitaxel (Abraxane®) Arm B will enroll patients with metastatic HER2-negative breast cancers, including triple-negative breast cancer (TNBC).” NCT04742959 ↗ “neoadjuvant treatment with nanoparticle albumin bound paclitaxel (Abraxane) every week for 12 weeks followed by 5-FU, epirubicin, and cyclophosphamide (FEC) every 3 weeks for 4 cycles” NCT00110695 ↗ “The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located.” NCT00833807 ↗ “Nab-Paclitaxel (Abraxane，ABI-007) with high effectiveness and low toxicity had been approved in breast cancer as first-line chemotherapy in many countries.” NCT01641783 ↗ “Investigational" means that the Albumin bound paclitaxel (Abraxane) is still being studied and that research doctors are trying to find out more about it.” NCT01698710 ↗ “Arm C: TT-00420 tablet in combination with nab-paclitaxel (Abraxane®) Arm C will enroll patients with advanced triple-negative breast cancer (TNBC).” NCT05253053 ↗ “A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer” NCT01298011 ↗ “A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 With or Without Nab-Paclitaxel (Abraxane) in Patients With Malignant Mesothelioma” NCT02798536 ↗ “The goal of this clinical research study is to find the highest tolerable dose of Abraxane® (nab-paclitaxel) when given directly into the liver” NCT01057264 ↗ “Abraxane, an albumin-bound formulation of paclitaxel has shown significant single-agent activity in breast cancer and in head and neck cancer.” NCT00319839 ↗ “Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles” NCT01783054 ↗ “Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest” NCT02142335 ↗ “A Phase I of ABI-010 (Nab-17-AAG) and ABI-007 (Abraxane) Administered Weekly in Patients With Advanced Non-Hematologic Malignancies” NCT00820768 ↗ “physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care” NCT02067416 ↗ “MBC patients with visceral metastases (N = 80) received nab-paclitaxel (Abraxane, 125 mg/m2, D1, D8, D15 every 28 days).” PMID 34727875 ↗ Nov 2021 “ABRAXANE® for Injectable Suspension \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]” NCT03563157 ↗ “Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability.” NCT01207102 ↗ “The 130-nm albumin-bound formulation of paclitaxel ([Abraxane, ABX ];Celgene,Summit,NJ) is a promising new agent” NCT01735409 ↗ “The goal of this clinical research study is to find the highest tolerable dose of Abraxane (nab-paclitaxel)” NCT00970996 ↗ “Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane)” NCT00748553 ↗ “nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing” NCT03714555 ↗ “Abraxane is a different form of paclitaxel that does not need to be dissolved by this solution.” NCT00642759 ↗ “standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.” NCT05557851 ↗ “Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer” NCT01493310 ↗ “ABRAXANE® [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]” NCT03563170 ↗ “abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1” NCT04590625 ↗ “ABI-007 (brand name Abraxane™) is a form of the chemotherapy drug called paclitaxel.” NCT00585689 ↗ “Nab-paclitaxel (Abraxane) 125mg/m\^2 + gemcitabine 1000mg/m\^2 (days 1, 8, 15, 28)” NCT03633734 ↗ “Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.” NCT02080221 ↗ “Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.” NCT02578732 ↗ “Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.” NCT02022033 ↗ “paclitaxel albumin-stabilized nanoparticle formulation (ABI-007; Abraxane\^®)” NCT00404404 ↗ “paclitaxel protein-bound particles (Abraxane) 260 mg/m\^2 IV every 3 weeks” NCT00281697 ↗ “Abraxane (nab-paclitaxel), Herceptin (trastuzumab) and carboplatin” NCT00617942 ↗ “Abraxane (paclitaxel albumin-stabilized nanoparticle formulation)” NCT00821964 ↗ “RX-3117 will be administered orally in combination with Abraxane.” NCT03189914 ↗ “Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV” NCT00262067 ↗ “ABI-007 (Abraxane, Nanoparticle Albumin-Bound Paclitaxel)” NCT00397761 ↗ “Abraxane® (nanoparticle albumin-bound paclitaxel)” NCT00479674 ↗ “Abraxane (nab-paclitaxel) + Gemzar (gemcitabine)” NCT02574663 ↗ “Another name for nab-paclitaxel is Abraxane®.” NCT03392571 ↗ “ABRAXANE® 75 mg/m2 over 30 min Days 5 and 12” NCT02581501 ↗ “Abraxane, which is a new form of paclitaxel” NCT00308178 ↗ “Abraxane® (Albumin-bound Paclitaxel)” NCT00409383 ↗ “Paclitaxel Protein Bound (Abraxane)” NCT03138720 ↗ “ABI-007 (Abraxane) and Carboplatin” NCT00274443 ↗ “Drug: Abraxane (nab-paclitaxel)” NCT03529175 ↗ “Abraxane:100-200 mg/m2，QD×1D” NCT05438797 ↗ “Nab-paclitaxel (Abraxane®)” NCT04617067 ↗ “Nab-paclitaxel (Abraxane)” NCT07578337 ↗ “nab-paclitaxel (Abraxane)” NCT01715142 ↗ “Paclitaxel = Abraxane” NCT03600623 ↗ “Other Name: Abraxane” NCT04753879 ↗ “ABI-007 (Abraxane)” NCT00503750 ↗ “ABI-007(Abraxane)” NCT00483301 ↗ |
| Known as | Abraxane (albumin-bound paclitaxel) | “Abraxane (albumin-bound paclitaxel)” NCT01667211 ↗ |
| Known as | Abraxane (nab-paclitaxel) | “Abraxane (nab-paclitaxel)” NCT01621243 ↗ |
| Known as | ABRAXANE ，Albumin-binding paclitaxel | “ABRAXANE ，Albumin-binding paclitaxel” NCT03959397 ↗ |
| Known as | Abraxane(Albumin-bound paclitaxel,nab-P) | “Abraxane(Albumin-bound paclitaxel,nab-P)” NCT01236716 ↗ |
| Known as | Abraxane, also ABI-007 | “Abraxane, also ABI-007” NCT01307891 ↗ |
| Known as | ABX | “The 130-nm albumin-bound formulation of paclitaxel ([Abraxane, ABX ];Celgene,Summit,NJ) is a promising new agent” NCT01735409 ↗1“Albumin-Bound Paclitaxel(ABX) intravenous drip” NCT06330337 ↗ |
| Known as | Albumin bound (nab)-paclitaxel | “Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide” NCT04067102 ↗ |
| Known as | albumin paclitaxel | “Although data have suggested that antiangiogenic agents may have some benefit to TNBC patients, there seems to be a lack of clinical trials evaluating efficacy and safety of...” NCT05192798 ↗97“AP regimen（Pemetrexed 500mg/m2+carboplatin AUC=5,q3w） for non-squamous cancer patientsor or TP regimen（Paclitaxel 175mg/m2+carboplatin AUC=5, or albumin paclitaxel...” NCT05378334 ↗ “Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2,...” NCT05182944 ↗ “After 2 courses of treatment with a combination of pembrolizumab and platinum containing dual drugs (albumin paclitaxel+carboplatin), surgery was performed and pembrolizumab...” NCT06304350 ↗ “Non-squamous NSCLC subjects will receive pemetrexed/albumin paclitaxel and platinum (cisplatin/carboplatin), and squamous NSCLC subjects will receive albumin paclitaxel and...” NCT06485557 ↗ “Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer...” NCT06278870 ↗ “The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel...” NCT06424899 ↗ “Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin:...” NCT05880082 ↗ “Epirubicin (E) 90\~100mg/m\^2, i.v., d1 + cyclophosphamide (C) 600 mg/m\^2, i.v., d1, q2w, for 4 cycles followed by albumin-paclitaxel (T) 260 mg/m\^2, i.v., d1, q2w, for 4 cycles.” NCT05341141 ↗ “AK104 (10 mg/kg d1), in combination with cisplatin (20 mg/m2 on d1-3) and albumin paclitaxel (100mg/m2 on d1,d8), fluorouracil (600 mg/m2 on d1-5) Q3W, intravenously” NCT05947201 ↗ “QL1706 in combination with albumin paclitaxel and gemcitabine or to receive QL1706 in combination with albumin paclitaxel, gemcitabine, and bevacizumab” NCT06313970 ↗ “Iparomlimab/Tuvonralimab 5mg/kg,D1,Q3W + albumin paclitaxel 90mg/m2, D1、8、15，Q3W+ Cisplatin 25mg/m2 or Carboplatin AUC = 1.5 , D1、8、15，Q3W” NCT07613567 ↗ “AK104 (10mg/kg ,Q3W，intravenously) plus chemotherapy（e.g. gemcitabine or albumin paclitaxel，dosage based on guidelines or instructions）” NCT06427057 ↗ “Regorafenib combined with Toripalimab and Albumin paclitaxel as the third line treatment for patients with advanced pancreatic cancer” NCT07040228 ↗ “administration regimen: Carillizumab 200mg, IV, D1; Albumin paclitaxel 150mg/m2, D1; Nedaplatin 50 mg/m2, D1; Apatinib 250mg Po D2-4.” NCT04666090 ↗ “TQB2916 injection combined with gemcitabine and albumin-paclitaxel as first-line treatment for metastatic pancreatic cancer” NCT06962267 ↗ “Paclitaxel：Docetaxel 75mg/m2, albumin paclitaxel 260mg/m2, or paclitaxel liposomes 175mg/m2) is administered intravenously” NCT06578299 ↗ “Albumin paclitaxel was administered intravenously (without pretreatment) for 30 min on the first day of each cycle” NCT05610332 ↗ “Neoadjuvant chemotherapy with TP regimen: albumin-paclitaxel + carboplatin, D1 administration) for 2 cycles.” NCT05244798 ↗ “Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.” NCT04326153 ↗ “Albumin-paclitaxel 130 mg/m², intravenous infusion on days 1 and 8, every 3 weeks (Q3W), total of 3 cycles” NCT07385001 ↗ “Albumin paclitaxel:260mg/ m2, administered intravenously every three weeks on the first day of each cycle” NCT05448781 ↗ “Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)” NCT05594095 ↗ “Drug: Pemetrexed, 500mg/m2 D1 IV Q3W or Albumin paclitaxel 260mg/m2，D1 or 130mg/m2，D1,8 IV Q3W” NCT06714708 ↗ “Albumin paclitaxel 100 mg/m2 D1, D8, intravenous infusion, 1 course of treatment every 21 days” NCT06636981 ↗ “Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6” NCT04499118 ↗ “Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area” NCT06705127 ↗ “Cadonilimab （Moderate dose）+ albumin paclitaxel 90mg/m2, qw×6+ cisplatin 25mg/m2, qw×6” NCT07400536 ↗ “Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes” NCT05214222 ↗ “Albumin paclitaxel: 100mg per bottle, 125mg/m2 IV Days 1, 8, cycled every 21 days” NCT05244993 ↗ “Albumin Paclitaxel + Carboplatin\*4 Followed by Epirubicin + Cyclophosphamide\*4” NCT07256964 ↗ “Albumin Paclitaxel，260mg/m2 IV every 3 weeks D1, 8(Q3W)，Other Name: Nab-PTX” NCT05833971 ↗ “camrelizumab+chemotherapy (Albumin-paclitaxel plus carboplatin)+Famitinib” NCT05999149 ↗ “squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W” NCT05787613 ↗ “Drug: Albumin Paclitaxel Injection specifications: 260mg/m2, IV D1 Q3W.” NCT05174325 ↗ “albumin paclitaxel 130 mg/m2, Days 1 and 8 + nedaplatin 80 mg/m2, Day 1” NCT06015035 ↗ “albumin paclitaxel: 125mg/m2, vgtt, d1, 8, q3w，for up to 6 cycles” NCT05673577 ↗ “Albumin-paclitaxel 175mg/m², carboplatin AUC = 4-5, d1, d22” NCT07457528 ↗ “pyrotinib combined with trastuzumab and albumin paclitaxel” NCT05429294 ↗ “Albumin-paclitaxel 80-100 mg/time on Days 1, 8, 15, and 22” NCT05497739 ↗ “Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）” NCT04290793 ↗ “albumin paclitaxel 260mg/m2 intravenous drip d1” NCT03650738 ↗ “Albumin paclitaxel 260mg/m2, ivgtt，D1 , Q3W” NCT07035392 ↗ “Drug: Albumin Paclitaxel” NCT04152057 ↗ |
| Known as | Albumin Taxol | “Drug: Albumin Taxol” NCT05610332 ↗ |
| Known as | albumin-binding paclitaxel | “All enrolled patients received carrilizumab combined with albumin-binding paclitaxel.” NCT05886140 ↗ |
| Known as | Albumin-bound paclitaxel | “BACKGROUND: For patients with untreated pancreatic ductal adenocarcinoma (PDAC), chemotherapy before surgery ("neoadjuvant therapy") has shown benefit in reducing recurrence...” PMID 42268676 ↗ Jun 202697“The purpose of this study was to investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of...” NCT00124943 ↗ “PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus...” PMID 22547591 ↗ Apr 2012 “with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel...” NCT05962021 ↗ “Albumin-bound paclitaxel is a novel, solvent-free, albumin-bound, 130 nanometer particle form of paclitaxel designed to avoid the problems associated with solvents used in...” NCT00398086 ↗ “this study aims to observe and explore the efficacy and safety of the combination of albumin-bound paclitaxel (keaili) and liposomal doxorubicin (duomeisu) in the treatment of...” NCT04859465 ↗ “A Single-center, Prospective, Phase II Study of Albumin-bound Paclitaxel (Nab-paclitaxel) and Carboplatin With or Without Trastuzumab (Herceptin) as Neoadjuvant Therapy in...” NCT01625429 ↗ “Albumin-bound paclitaxel(nab-paclitaxel) has been used to treat a variety of malignancies such as non-small cell lung cancer, pancreatic cancer, breast cancer, melanoma,...” NCT04077983 ↗ “Paclitaxel Powder For Injectable Suspension Nanoparticle, Albumin-bound Paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with...” NCT06783140 ↗ “TPF (Paclitaxel micelles or albumin-bound paclitaxel 100 mg/m2, cisplatin 30 mg/m2, fluorouracil 200 mg/m2 IV drip + 1000 mg/m2 pump for 44 hours, leucovorin/calcium 200 mg) +...” NCT07469241 ↗ “Investigator-selected chemotherapy includes injectable taxanes (paclitaxel injection, albumin-bound paclitaxel, docetaxel, etc.), irinotecan, etc., excluding oral paclitaxel solution.” NCT07552402 ↗ “Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;” NCT06231680 ↗ “Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trial.” PMID 41937137 ↗ Apr 2026 “Enrolled participants received two cycles of induction albumin-bound paclitaxel (260 mg/m2, d1), cisplatin (60 mg/m2, d1), and toripalimab (240 mg, d1) every three weeks” PMID 42028290 ↗ Apr 2026 “Albumin-bound paclitaxel is a novel, solvent-free, albumin-bound nanoparticle form of paclitaxel designed to avoid problems associated with solvents used in Taxol.” NCT01667211 ↗ “Non-small cell lung cancer (squamous cell carcinoma) : paclitaxel/albumin-bound paclitaxel + carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles.” NCT06276933 ↗ “HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab will be administrated per dose level in which the patients are assigned.” NCT07131514 ↗ “A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer” NCT07040228 ↗ “Investigational" means that the Albumin bound paclitaxel (Abraxane) is still being studied and that research doctors are trying to find out more about it.” NCT01698710 ↗ “Patients were treated with albumin-bound paclitaxel 100 mg/m2 and carboplatin at area under the curve (AUC) = 2 on days 1, 8, and 15 of a 28-day cycle.” PMID 20705560 ↗ Aug 2010 “HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.” NCT04150575 ↗ “Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.” NCT03825328 ↗ “Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas” NCT00844649 ↗ “Participants will receive albumin bound paclitaxel (ABRAXANE®) 100 mg/m2 administered as an intravenous infusion over 30 minutes” NCT02215447 ↗ “Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1” NCT04581265 ↗ “Albumin-bound paclitaxel 260 mg/m², carboplatin AUC = 5, intravenous infusion, Day 1, every 3 weeks for 2 cycles.” NCT07584031 ↗ “Albumin bound paclitaxel 125mg / m² followed by Gemcitabine 1000mg / m² followed by 2 weeks of rest” NCT05065801 ↗ “Albumin-bound paclitaxel: 125 mg/m² intravenous infusion on Days 1 and 8, every 3 weeks per cycle.” NCT07240766 ↗ “(Note: Gemcitabine can be replaced by docetaxel, albumin-bound paclitaxel, paclitaxel, etc.)” NCT07328854 ↗ “Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W；” NCT06086457 ↗ “Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W” NCT06475755 ↗ “gemcitabine and albumin-bound paclitaxel will be administered at a protocol-defined dose” NCT06835569 ↗ “Albumin-bound paclitaxel 50 mg/m² plus cisplatin 25 mg/m², administered weekly (QW).” NCT07086456 ↗ “albumin-bound paclitaxel + platinum-based treatment (lung squamous cell carcinoma)” NCT06403111 ↗ “Second Phase of Neoadjuvant Chemotherapy: Albumin-bound Paclitaxel + Toripalimab.” NCT06682195 ↗ “albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.” NCT06130332 ↗ “Albumin-Bound Paclitaxel(Nab-Paclitaxel):125mg/m2,ivgtt,d1,d8,21days/cycle” NCT04722718 ↗ “Albumin-bound Paclitaxel: 260mg/m², IV infusion, Day 1 (21 days per cycle)” NCT06848439 ↗ “Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min” NCT03162510 ↗ “Albumin-bound paclitaxel: 260 mg/m², intravenous infusion over 30 minutes” NCT07581795 ↗ “Albumin-bound paclitaxel: IV, 100 mg/m², Day1, 8, 15; or 260 mg/m2, Q3W” NCT05979818 ↗ “Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin” NCT06084897 ↗ “Albumin-bound paclitaxel: 100 mg/m² by IV infusion” NCT06978829 ↗ “Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W” NCT06062485 ↗ “Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07248956 ↗ “Albumin-bound paclitaxel: 125mg/m2, D1,8, Q3W” NCT07347444 ↗ “Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07547332 ↗ “Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT06511726 ↗ “Albumin-bound paclitaxel: 260 mg/m2” NCT07388095 ↗ “albumin-bound paclitaxel (nab-P)” NCT04137653 ↗ “Drug: Albumin-bound paclitaxel” NCT05947487 ↗ “Albumin-Bound Paclitaxel” NCT04766359 ↗ |
| Known as | Albumin-bound paclitaxel for Injection | “Albumin-bound paclitaxel for Injection” NCT06939270 ↗ |
| Known as | albumin-bound paclitaxel; paclitaxel protein-bound particles for injectable suspension (albumin-bound); Nab-paclitaxel Brand name: Abraxane | “albumin-bound paclitaxel; paclitaxel protein-bound particles for injectable suspension (albumin-bound); Nab-paclitaxel Brand name: Abraxane ®” NCT02769832 ↗ |
| Known as | albuminotaxol | “paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.” NCT06775275 ↗ |
| Known as | Anzatax | “Anzatax” NCT06323460 ↗ |
| Known as | Asotax | “Asotax” NCT07281417 ↗ |
| Known as | Capxol | “Capxol” NCT00732836 ↗ |
| Known as | DHP107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03326102 ↗ |
| Known as | EndoTAG-1 | “This is a prospective, multicenter, open-label, randomized, and controlled trial to test the superiority of EndoTAG®-1 in combination with paclitaxel and gemcitabine versus...” NCT03002103 ↗ |
| Known as | Genexol | “D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs” NCT00816634 ↗ |
| Known as | Genexol-PM | “This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose of the combination therapy with Genexol®-PM and Carboplatin and to evaluate the...” NCT00877253 ↗10“To evaluate the efficacy and safety Genexol-PM(CrEL-free polymeric micelle formulated paclitaxel)and gemcitabine in untreated metastatic NSCLC patients” NCT01770795 ↗ “Genexol-PM is a novel Cremophor® EL (CrEL)-free polymeric micelle formulation of paclitaxel.” PMID 22012004 ↗ Oct 2011 “Paclitaxel loaded polymeric micelle (Genexol-PM®)” NCT01023347 ↗ |
| Known as | Ke ai li | “this study aims to observe and explore the efficacy and safety of the combination of albumin-bound paclitaxel (keaili) and liposomal doxorubicin (duomeisu) in the treatment of...” NCT04859465 ↗1“Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)” NCT04017377 ↗ |
| Known as | Kealil | “albumin-bound paclitaxel injection (Kealil)” NCT06078670 ↗ |
| Known as | LDE-paclitaxel | “Paclitaxel carried by a lipid nanoparticle (LDE-Paclitaxel)” NCT04148833 ↗ |
| Known as | LEP-ETU | “LEP-ETU is a new formulation of the anti-cancer agent paclitaxel for injection or Taxol (paclitaxel and Cremophor EL).” NCT00080418 ↗1“Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) is being compared to Taxol®” NCT00100139 ↗ |
| Known as | Lipid Complexed Paclitaxel | “Weekly Infusions of Gemcitabine and Twice Weekly Administration of Lipid Complexed Paclitaxel (EndoTAG-1)” NCT00377936 ↗ |
| Known as | Micellar Paclitaxel | “using intravenous Micellar Paclitaxel (75 mg/m(2) every 4 weeks) for six months.” NCT00006276 ↗ |
| Known as | Nab | “PURPOSE: This randomized phase-II trial (ClinicalTrials.gov identifier: NCT02767557) compared efficacy of gemcitabine/nab-paclitaxel (Gem/Nab) with or without the...” PMID 40354592 ↗ May 2025 |
| Known as | nab-P | “The GBG69 study was the first to compare the efficacy and safety of nab-paclitaxel (nab-P) and solvent-based paclitaxel in the neoadjuvant treatment of breast cancer.” NCT05420454 ↗3“At baseline, patients receive the Nab-P+HP regimen (albumin-bound paclitaxel plus trastuzumab and pertuzumab).” NCT07239271 ↗ “Nab-paclitaxel (NAB-P)/Gemcitabine (G) versus G alone.” PMID 33812334 ↗ Mar 2021 “Drug: nab-Paclitaxel (nab-P)” NCT06964906 ↗ |
| Known as | nab-pac | “Abraxane (nab-pac, Celgene) is a novel 130 nm, albumin-bound (nab) nanoparticle formulation of paclitaxel which has noteworthy single-agent activity and a favourable toxicity...” NCT03304210 ↗ |
| Known as | nab-paclitaxel | “Patients will be administered with appropriate adjuvant chemotherapy regimens including but are not limited to: GEM monotherapy/adjustable GEM monotherapy, S-1...” NCT06966440 ↗1078“BACKGROUND AND PURPOSE: Nab-paclitaxel is a promising albumin-bound paclitaxel with a therapeutic index superior to that of docetaxel, but the optimal dose of nab-paclitaxel...” PMID 38135184 ↗ Dec 2023 “Fudan CUP-002 study (ClinicalTrials.gov identifier: NCT04848597), an investigator-initiated prospective trial, was designed to evaluate the efficacy and safety of an anti-PD-1...” PMID 42103741 ↗ May 2026 “Squamous cell carcinoma: Paclitaxel (175mg/m²) or Docetaxel (60-75 mg/m²) or Nab-paclitaxel (260mg/m²) plus Carboplatin (AUC=5)/Cisplatin (75 mg/m²) (to be determined by...” NCT07608159 ↗ “The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given...” NCT03410030 ↗ “Acceptable histology-specific PDC regimens include carboplatin plus paclitaxel or nab-paclitaxel (any histology), carboplatin/cisplatin plus pemetrexed (nonsquamous),...” NCT06865339 ↗ “This is an open label Phase II study to evaluate the clinical activity of the combination of gemcitabine and nab-paclitaxel (abraxane) as second line treatment in patients with...” NCT02242409 ↗ “This phase II trail will evaluate the efficacy and safety of combining gemcitabine hydrochloride, cisplatin, nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle...” NCT06591650 ↗ “Nab-Paclitaxel : 260 mg/m2, intravenous infusion, d1, 3-week cycle, 3 cycles; Cisplatin: 75 mg/m2, intravenous infusion, d1, once every 3 weeks, for a total of 3 cycles;...” NCT05522985 ↗ “This phase II trial studies nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation) and carboplatin followed by response-based local therapy in treating...” NCT02258659 ↗ “This phase I/II trial studies the side effects, maximum tolerated dose, and effectiveness of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) in treating...” NCT01555853 ↗ “The chemotherapy included nab-paclitaxel (100 mg/m2) and carboplatin (area under the curve, 1.5) on days 1, 8, and 15 in 28-day cycles for the first 16 weeks followed by...” PMID 39671272 ↗ Feb 2025 “The objective of this research is to find out what effects (good and bad), the sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX, the standard...” NCT05825066 ↗ “Standard first-line systemic chemotherapy administered according to institutional guidelines (e.g., modified FOLFIRINOX or gemcitabine plus nab-paclitaxel), followed by...” NCT07407231 ↗ “Combined with Toripalimab, Nab-paclitaxel will be dosed at 125 mg/m² based on body surface area, administered by intravenous infusion weekly (Days 1, 8, 15 of each 21-day...” NCT06914440 ↗ “PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus...” PMID 22547591 ↗ Apr 2012 “There is increasing evidence that combination therapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and programmed cell death protein 1 (PD-1) inhibitor is safe...” NCT05189483 ↗ “Participating patients will receive the GnP regimen every 21 days (nab-paclitaxel 125mg/m² ivgtt on days 1 and 8 + gemcitabine 1000mg/m² ivgtt on days 1 and 8, repeated every...” NCT07101679 ↗ “PD-1 inhibitor plus TP or GP regimen chemotherapy (Paclitaxel or Liposomal Paclitaxel + Carboplatin or Cisplatin , nab-paclitaxel + Carboplatin or Cisplatin, Gemcitabine +...” NCT07337096 ↗ “The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken...” NCT06664983 ↗ “Efficacy and Safety of Serplulimab Combined With Nab-paclitaxel and SOX as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric...” NCT06576921 ↗ “The study is aimed to evaluate the efficacy of investigator's choice (ICC) of chemotherapy (nab-paclitaxel, capecitabine, eribulin, carboplatin, vinorelbine, or utidelone)...” NCT05954442 ↗ “Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel,...” NCT05383001 ↗ “Nab-paclitaxel in combination with gemcitabine is routinely used as second-line therapy in metastatic PDAC patients who have either progressed on or are intolerant to 5-FU...” NCT07049055 ↗ “Patients received nab-paclitaxel at starting dose of 125 mg/m2 intravenously on days 1 and 8 and pembrolizumab 200 mg intravenously on day 1 in 21-day cycles until progression,...” PMID 36317715 ↗ Nov 2022 “Drug: Taxane chemotherapy Docetaxel, 75mg/m², D1, Q3W, iv drip, maximum 6 cycles; or paclitaxel, 175mg/m², D1, Q3W, iv drip, maximum 6 cycles; or nab-paclitaxel, 260mg/m², D1,...” NCT07581821 ↗ “To evaluate the efficacy (overall response rate) of single agent nab-paclitaxel (Abraxane) (paclitaxel albumin-stabilized nanoparticle formulation) in patients with relapsed or...” NCT01646762 ↗ “Albumin-bound paclitaxel(nab-paclitaxel) has been used to treat a variety of malignancies such as non-small cell lung cancer, pancreatic cancer, breast cancer, melanoma,...” NCT04077983 ↗ “For non-squamous, the standard chemotherapy option of choice is carboplatin and pemetrexed. For squamous cell carcinoma, the chemotherapy used would be carboplatin and...” NCT05691829 ↗ “Cadonilimab (10 mg/kg, administered on the first day of each cycle, Q3W, until there is no clinical benefit)+Nab-Paclitaxel(200 mg/m2, Q3W ,6 cycles), every 3 weeks (21 days)...” NCT06009848 ↗ “combination therapy of cadonilimab(Bispecific Anti-PD-1/CTLA-4 Antibody) plus nab-Paclitaxel in patients with recurrent or metastatic cervical cancer that had failed PD-1/PD-L1...” NCT05824494 ↗ “Taxanes (paclitaxel, docetaxel, liposomal paclitaxel, nabpaclitaxel), vinorelbine, capecitabine, eribulin, and other chemotherapeutic agents indicated in advanced breast cancer...” NCT05621434 ↗ “All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical...” NCT05554276 ↗ “Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or...” NCT03398291 ↗ “We conduct a randomized phase 3, controlled, open-label trial to compare nab-paclitaxel/cisplatin (AP) with gemcitabine/cisplatin (GP) in mTNBC patients (ClinicalTrials.gov...” PMID 35821019 ↗ Jul 2022 “One of the following Treatment of Physician Choice will be administered per standard of care: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel” NCT01492101 ↗ “Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)” NCT07034742 ↗ “The combination of nab-paclitaxel (now called paclitaxel protein bound) and gemcitabine had a high response and survival in the phase I and II study in advanced pancreatic cancer.” NCT03138720 ↗ “Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles.” NCT01470417 ↗ “Induction Therapy: Two cycles of induction chemotherapy (nab-paclitaxel 200 mg/m², day 1; carboplatin AUC 5, day 1) combined with a PD-1 inhibitor (200 mg, day 1) every 3 weeks.” NCT05621707 ↗ “Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.” NCT06218004 ↗ “Patients will receive nab-paclitaxel 125 mg/m\^2 followed by gemcitabine 1,000 mg/m\^2 as one intravenous infusion over 30-40 minutes on days 1 and 8 of every 21-day cycle.” NCT06722911 ↗ “* Nab-paclitaxel 100mg/m2 in NS dilute to a total concentration of 5 mg/mL (DO NOT FILTER) over 30 minute IV infusion on days 1 and 8 repeated every 21 days, followed by:” NCT04546828 ↗ “In this phase II trial, carboplatin with nanoparticle albumin-bound (nab)-paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC) was evaluated.” PMID 26123189 ↗ May 2015 “PURPOSE: To evaluate intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies that are primarily confined to the peritoneal cavity in a phase I trial.” PMID 30623229 ↗ Jan 2019 “In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer.” PMID 24131140 ↗ Oct 2013 “Carboplatin + choice of non-platinum chemotherapy drug: taxane, paclitaxel, nab-paclitaxel, gemcitabine or doxorubicin pegylated liposomal with or without bevacizumab.” NCT02759588 ↗ “The GBG69 study was the first to compare the efficacy and safety of nab-paclitaxel (nab-P) and solvent-based paclitaxel in the neoadjuvant treatment of breast cancer.” NCT05420454 ↗ “Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.” NCT04585477 ↗ “The 130 nm albumin bound paclitaxel (nab-paclitaxel, ABI-007) delivers more paclitaxel to tumor than conventional paclitaxel without cremophor related toxicities.” PMID 24318901 ↗ Dec 2013 “Administered intravenously: carboplatin (AUC=5), nab-paclitaxel (260 mg/m²) + 200 mg Sintilimab + Bevacizumab (7.5 mg/kg), every 3 weeks for a total of 12 weeks.” NCT07351487 ↗ “Nab-Paclitaxel (Abraxane，ABI-007) with high effectiveness and low toxicity had been approved in breast cancer as first-line chemotherapy in many countries.” NCT01641783 ↗ “In NCT01149798, seventy-three MBC patients received 125 mg/m2 nab-paclitaxel on days 1, 8 and 15 followed by 75 mg/m2 cisplatin on day 1 of a 28-day cycle.” PMID 30837503 ↗ Mar 2019 “Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.” NCT01698281 ↗ “Nab-paclitaxel is a nanoparticle albumin-bound paclitaxel that showed anti-tumor activity as well as synergistic effect in combination with gemcitabine.” NCT03502343 ↗ “Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.” NCT06152978 ↗ “Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle” NCT02125136 ↗ “Patients secondly receive nab-paclitaxel 100 mg/m2 (iv, at least 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment.” NCT04498689 ↗ “Patients receive paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel) IV over 30 minutes on days 1, 8, 15, 22, 29, 36, 43, and 50.” NCT00499291 ↗ “nab-paclitaxel (120 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8, and 15 every 4 weeks.” NCT06601283 ↗ “two-drug chemotherapy group, including gemcitabine-based combination regimens (predominately gemcitabine/nab-paclitaxel or gemcitabine/capecitabine)” NCT06867146 ↗ “Standard of care regimen for intravenous infusions of gemcitabine and nab-paclitaxel weekly for three weeks followed by one week without an infusion” NCT07562152 ↗ “A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer” NCT01298011 ↗ “Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.” PMID 35242683 ↗ Jan 2022 “Eligible patients will receive neoadjuvant treatment: 360 mg nivolumab IV on Day 1 plus 125 mg/m2 nab-paclitaxel on Day 1 and 8, in a 21-day cycle.” NCT04876313 ↗ “Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer” NCT04731467 ↗ “Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC):Pemetrexed: 500 mg/m\^2, ivgtt, day 1. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1.” NCT06617936 ↗ “Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.” NCT04914390 ↗ “They were given serplulimab 4.5 mg/kg for up to 2 years (35 dosing cycles) plus nab-paclitaxel 260 mg/m2 for up to six cycles once every 3 weeks.” PMID 37153587 ↗ Apr 2023 “In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.” NCT04153734 ↗ “and Nab-paclitaxel: carboplatin, AUC=5, D1, IV, q3w, or cisplatin, 75 mg/m2, IV, q3w, and Nab-paclitaxel, 130 mg/m2, D1, IV, q3w, for 3-4 cycles.” NCT05055583 ↗ “Nab-paclitaxel: 125mg/m2 intravenously, D1, D8, q3w, 4-6 cycles;Intravenous infusion of 100 mg, D1, qw is used at the same time as radiotherapy.” NCT06464614 ↗ “This study aimed to investigate the efficacy and safety of nab-paclitaxel combined with simvastatin as second-line treatment for SCLC patients.” PMID 41937137 ↗ Apr 2026 “A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.” PMID 23706253 ↗ May 2013 “Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.” NCT04031885 ↗ “SINE compounds synergize with gemcitabine (GEM) and nanoparticle albumin-bound (nab)-paclitaxel leading to suppression of PDAC cellular growth” PMID 31831564 ↗ Dec 2019 “Platinum-based chemotherapy (carboplatin AUC=5 + pemetrexed 500 mg/m² [adenocarcinoma] or nab-paclitaxel 260 mg/m² [squamous/other subtypes])” NCT06977074 ↗ “HLX22 (15 mg/kg IV) + trastuzumab (8 mg/kg loading dose → 6 mg/kg maintenance) + nab-paclitaxel (125 mg/m² IV) + gemcitabine (1000 mg/m² IV).” NCT07176702 ↗ “Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer” NCT01830244 ↗ “nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter) on days 1, 8 every 3 weeks” NCT05869474 ↗ “Possible regimens are either mFOLFIRINOX or NALIRIFOX or Gemcitabine Nab-Paclitaxel ± Cisplatin (GA+/-Cisplatin) or Capecitabine (Xeloda).” NCT06831136 ↗ “Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)” NCT05984342 ↗ “Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles” NCT06421376 ↗ “Nab-paclitaxel (125 mg/m²), administered by intravenous infusion on Day 1 and Day 8 of each 21-day cycle (Q3W), for a total of 4 cycles.” NCT07254858 ↗ “Nab-paclitaxel is a taxane derivative that is an albumin-bound paclitaxel nanoparticle formulation that promotes microtubule assembly.” NCT04964960 ↗ “Immune checkpoint blockade antibody ATEZOLIZUMAB directed against PD-L1 (Programmed death-ligand 1); Carboplatin; Nab-Paclitaxel (iv)” NCT04865250 ↗ “nab-Paclitaxel 125 mg/m\^2 will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles.” NCT06405685 ↗ “Patients of SD with 2 cycles of dual therapy wlii receive triple therapy regimen: Camrelizumab and Famitinib with nab-Paclitaxel.” NCT05670925 ↗ “nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.” NCT03377491 ↗ “Gemcitabine (1000 mg/m\^2) and Nab-paclitaxel (125 mg/m\^2) administered intravenously on Day 1 and Day 8 of each 3-week cycle.” NCT07312422 ↗ “Nab-paclitaxel: 125mg/m², intravenous infusion, on Day 1 and Day 8, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment” NCT06952621 ↗ “Nab-paclitaxel 100mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.” NCT05843292 ↗ “Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.” NCT05586516 ↗ “Nab-paclitaxel, also known as nanoparticle albumin-bound paclitaxel, is a chemotherapy drug used to treat certain cancers.” NCT07134413 ↗ “MBC patients with visceral metastases (N = 80) received nab-paclitaxel (Abraxane, 125 mg/m2, D1, D8, D15 every 28 days).” PMID 34727875 ↗ Nov 2021 “platinum-free albumin bound paclitaxel (nab-paclitaxel) combined with camrelizumab and apatinib as first-line treatment” PMID 38261958 ↗ Jan 2024 “Nab-paclitaxel (125 mg/m²) + saline (100 mL), infused intravenously over 30 minutes, followed by a 100 mL saline flush” NCT06825546 ↗ “gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) - another standard regimen in this setting - will be used.” NCT04594772 ↗ “nab-paclitaxel One course will last 21 days. Given twice every 3 weeks at a dose of 260 mg/m2 in day 1 and day 8.” NCT05524974 ↗ “TC : paclitaxel 135mg/m2, or nab-paclitaxel paclitaxel 180mg/m2, d1, iv, carboplatin AUC=5, d1, iv, q3w，2 cycles.” NCT07112833 ↗ “Chemotherapy of Physician's Choice, including nab-paclitaxel, Eribulin, Capecitabine, Vinorelbine, Gemcitabine.” NCT07203729 ↗ “nab-paclitaxel 135 mg/m2, d1, 8 and carboplatin AUC 5, d1 every 3 weeks; pemetrexed, 500mg/m2 d1 every 3 weeks” NCT05800340 ↗ “nab-paclitaxel 100 mg/m2 on days 1, 8, and 15, every 3 weeks plus carboplatin AUC 5 on days 1 every 3 weeks” NCT06175390 ↗ “Gemcitabine + nab-paclitaxel demonstrated a significant survival improvement compared to gemcitabine alone” NCT02358161 ↗ “combined regimen of Durvalumab (anti-PD-L1 antibody), Lenvatinib and Paclitaxel albumin (nab-paclitaxel).” NCT05327582 ↗ “followed by intravenous cisplatin 75 mg/m2 plus nab paclitaxel 220 mg/m2 every 3 weeks for up to 6 cycles” PMID 37491309 ↗ Jul 2023 “NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.” NCT02506803 ↗ “Systemic AG chemotherapy (nab-paclitaxel 125mg/m²+ gemcitabine 1000mg/m², initiated, Day 1,8,15, q4 week)” NCT06946901 ↗ “Patients receive ivonescimab in combination with nab-paclitaxel + cisplatin for 3 cycles before surgery.” NCT06444009 ↗ “T: docetaxel, nab-paclitaxel or paclitaxel. Routine clinical dosage and administration shall be adopted.” NCT07410234 ↗ “Alternatively nab-paclitaxel weekly can be used (if paclitaxel cannot be used due to allergic reaction).” NCT07102940 ↗ “Nab-paclitaxel is designed to block cancer cells from dividing, which may cause the cancer cells to die.” NCT01057264 ↗ “nab-paclitaxel 260 mg/m2 plus platinum [carboplatin AUC 5, or cis-platinum 75 mg/m2] for squamous NSCLC” PMID 39756446 ↗ Jan 2025 “pemetrexed (500 mg/m2 for non-squamous carcinoma) or nab-paclitaxel (260 mg/m2 for squamous carcinoma)” NCT06709859 ↗ “Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.” NCT04995120 ↗ “Nab-paclitaxel: 260 mg/m², iv over 30 minutes, administered on Day 1, Q3W, for a maximum of 6 cycles.” NCT07509099 ↗ “Eligible subjects will receive 4 cycles carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab.” NCT04554524 ↗ “Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle.” NCT03329950 ↗ “combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin” NCT03908333 ↗ “possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)” NCT04990609 ↗ “the specific TC chemotherapy regimen is as follows: nab-paclitaxel 260 mg/m², intravenous infusion” NCT07271602 ↗ “nab-paclitaxel (120 mg per square meter of body-surface area) on days 1, 8, and 15 every 4 weeks.” NCT06017284 ↗ “gemcitabine and nanoparticle albumin bound paclitaxel (nab-paclitaxel) every 14 days for 4 cycles” NCT02626520 ↗ “Nab-paclitaxel is designed to block cancer cells from dividing, which may cause the cells to die.” NCT00732836 ↗ “Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab” NCT06438627 ↗ “standard of care (SOC) nanoparticle albumin-bound (nab)-paclitaxel (Abraxane) plus gemcitabine.” NCT05557851 ↗ “All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.” NCT04045730 ↗ “TPC choice includes nab paclitaxel (100 mg/m\^2 Intravenous on day 1,8 \&15 of a 28 day cycle)” NCT01802970 ↗ “Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy)” NCT05547828 ↗ “sequential systemic therapy with ipilimumab N01, sintilimab, nab-paclitaxel, and gemcitabine” NCT07683221 ↗ “Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W；” NCT06086457 ↗ “GN: gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2, every 21 days (3 weeks/cycle).” NCT06278454 ↗ “gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle” NCT07277452 ↗ “either nab-paclitaxel (Abraxane®) or gemcitabine (Gemzar®) plus carboplatin (Paraplatin®)” NCT03567720 ↗ “gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle” NCT06938503 ↗ “Nab-paclitaxel 100 mg/m² administered intravenously during neoadjuvant treatment cycles.” NCT07628062 ↗ “AG: intravenous nab-paclitaxel 125 mg/m2 and gemcitabine 1000mg/m2 d1,8, q3w, 4 cycles.” NCT06435260 ↗ “Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles” NCT05418309 ↗ “with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors” PMID 35338084 ↗ Mar 2022 “gemcitabine 1,000 mg/m2 and nab-paclitaxel 125 mg/m2 intravenously on days 1, 8 and 15” PMID 41187298 ↗ Nov 2025 “combined with Gemcitabine and Nab-Paclitaxel IV infusion at day1, 8, a 21-day cycle” NCT06266143 ↗ “Nab-paclitaxel (Abraxane) 125mg/m\^2 + gemcitabine 1000mg/m\^2 (days 1, 8, 15, 28)” NCT03633734 ↗ “Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles” NCT06198907 ↗ “Could be paclitaxel, docetaxel or Nab-paclitaxel, according to physician's choice.” NCT07317778 ↗ “Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles.” NCT02684461 ↗ “Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle” NCT07235930 ↗ “nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 +cisplatin 25 mg/m2 IV infusion” NCT06076837 ↗ “Nab-paclitaxel:125 mg/m2, ivgtt, D1, 8 and 15,every 6 weeks for a treatment cycle” NCT06393166 ↗ “Gemcitabine 1000mg/m\^2 and nab-paclitaxel 125mg/m\^2, administered intravenously” NCT04603586 ↗ “PAXG (cisplatin, nab-paclitaxel, capecitabine, and gemcitabine) over mFOLFIRINOX” PMID 41275879 ↗ Nov 2025 “intravenous (IV) infusion of nab-paclitaxel at a dose of 125 mg per square meter” NCT05239182 ↗ “Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin)” NCT07092449 ↗ “and nab-paclitaxel 135-175 mg/m² by intravenous infusion on day 1 of each cycle” NCT07340489 ↗ “Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel” NCT04418154 ↗ “Nab-paclitaxel is a standard second-line treatment for advanced gastric cancer” PMID 40554667 ↗ Jul 2025 “cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab” NCT06383780 ↗ “Drug: Nab-Paclitaxel 220-260 mg/m2 on Day 1 of each 3-week cycle for 2 cycles” NCT06354530 ↗ “nab-paclitaxel + carboplatin + trastuzumab + pertuzumab (PCbHP, control arm)” NCT07528716 ↗ “Chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles” NCT07162506 ↗ “Nab-paclitaxel plus Cisplatin plus Toripalimab (TP plus Toripalimab regimen)” NCT07362979 ↗ “nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d” NCT03917069 ↗ “followed by nab-paclitaxel + Benmelstobart administered by intravenous drip” NCT06874933 ↗ “NAB paclitaxel (100 mg/m2 IVI) every week (d1,8,15) in three weekly cycle.” NCT02215447 ↗ “* nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).” NCT04176952 ↗ “* nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first)” NCT04151277 ↗ “Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w” NCT05346107 ↗ “Nab-paclitaxel 100 mg/m2 IV over 1-2 hours on day 1 and day 8 q 3 weekly” NCT07062263 ↗ “investigator-selected taxane (docetaxel, paclitaxel, or nab-paclitaxel)” PMID 41576297 ↗ Jan 2026 “paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel)” NCT01566435 ↗ “Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2” NCT03750669 ↗ “Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.” NCT04253964 ↗ “Nab-paclitaxel 125 mg/m² and gemcitabine 1000 mg/m² IV on Days 1 and 8” NCT07053150 ↗ “regimen includes: 1) Nab-paclitaxel; 2) Carboplatin; 3) Pembrolizumab.” NCT07618793 ↗ “Chemotherapy (TPF regimen): nab-paclitaxel 175mg/m2, on the 1st day;” NCT05351762 ↗ “FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy.” NCT06333314 ↗ “(gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)” NCT06404840 ↗ “The RP2D was pemetrexed 500 mg/m(2) and nab-paclitaxel 260 mg/m(2).” PMID 24013936 ↗ Sep 2013 “intravenous nab-paclitaxel 120 mg/m2 on days 1 and 8 of each cycle” PMID 33435909 ↗ Jan 2021 “Nab-Paclitaxel will be delivered at day 1 at the dose of 125mg/m2.” NCT03199144 ↗ “Abraxane (nab-paclitaxel), Herceptin (trastuzumab) and carboplatin” NCT00617942 ↗ “Paclitaxel, Nab-paclitaxel, Capecitabine, Eribulin, or Carboplatin” NCT06732323 ↗ “nab-paclitaxel (100 mg/m², Days 1, 8, 15, every 4 weeks per cycle)” NCT07371208 ↗ “Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes.” NCT01461915 ↗ “Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.” NCT06091943 ↗ “added to nab-paclitaxel 125 mg/m2 on days 1 and 8, every 21 days” NCT06341478 ↗ “T: Taxanes, including docetaxel, nab-paclitaxel, and paclitaxel.” NCT07378306 ↗ “namely nab-paclitaxel (125 mg/m2, 5 days before cell infusions)” NCT05699811 ↗ “Nab-paclitaxel or pemetrexed (per histology), intravenously Q3W” NCT07550920 ↗ “pemetrexed/paclitaxel/nab-paclitaxel plus carboplatin/cisplatin” NCT07603661 ↗ “Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed” NCT03774732 ↗ “NAB-PACLITAXEL 125 mg/m2 (30 min infusion) on day 1, 8 and 15.” NCT07616362 ↗ “gemcitabine plus S-1 versus gemcitabine plus nab-paclitaxel” NCT05268692 ↗ “AG Chemotherapy: Nab-paclitaxel + Gemcitabine for 8 cycles.” NCT07328802 ↗ “TGI chemotherapy (nab⁃Paclitaxel+ gemcitabine + ifosfamide)” NCT06816771 ↗ “Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle.” NCT04808687 ↗ “Nab-paclitaxel (ABRAXANE) will be administered as follows:” NCT03275818 ↗ “Nab-paclitaxel will be dosed per local practice and label” NCT03138889 ↗ “Nab-Paclitaxel: 100mg/m2 on day 1, 8 and 15 every 4 weeks” NCT05841420 ↗ “weekly nab-paclitaxel (50 mg/m2) and carboplatin (AUC=2)” PMID 40834785 ↗ Aug 2025 “and \[nab\]-paclitaxel (100mg/m2) for the first 4 cycles” NCT04094909 ↗ “Gemcitabine (1,000 mg/m2) and nab-paclitaxel (125 mg/m2)” NCT07280377 ↗ “Nab-paclitaxel: 200 mg/m², intravenous infusion on Day 1” NCT07706985 ↗ “Weekly nab-paclitaxel and cisplatin during radiotherapy” NCT07609121 ↗ “Nab-paclitaxel (125 mg/m2) once weekly (QW) for 4 weeks” NCT05909332 ↗ “Paclitaxel / NAB-Paclitaxel, 175 / 260mg / m2, D1, Q3w” NCT05243355 ↗ “Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks” NCT04902261 ↗ “Nab-paclitaxel: 100 mg/m2. Intravenous administration” NCT04826016 ↗ “Nab-paclitaxel 100 mg per square meter, d1,d8,d15 q3w” NCT07393425 ↗ “chemotherapy (nab-paclitaxel, 130 mg/m2 or pemetrexed” NCT06241807 ↗ “nab-paclitaxel 125 mg/m2 weekly on day 1 for 12 weeks” PMID 36426808 ↗ Jan 2023 “Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8” NCT04711824 ↗ “nab-Paclitaxel 100 mg/m2 day 1 and 8 every 21 days” NCT02632305 ↗ “Nab-paclitaxel (on days 1 and 8 of a 21-day cycle)” NCT07057427 ↗ “in combination with gemcitabine and nab-paclitaxel” NCT06944106 ↗ “Two cycles of nab-paclitaxel at 260 mg/m2 on day 1” NCT06811844 ↗ “80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly” NCT02789657 ↗ “nab-Paclitaxel 125mg/m2，iv，D1,8,15, 28days/cycle” NCT04324307 ↗ “nab-paclitaxel (260mg/m2) IV Q3W for 4-6 circle” NCT04976647 ↗ “taxane (paclitaxel, nab-paclitaxel or docetaxel” NCT05172518 ↗ “Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2” NCT07147426 ↗ “Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07248956 ↗ “nab-paclitaxel at a dose of 200 mg/m² on day 1” NCT06341998 ↗ “Another name for nab-paclitaxel is Abraxane®.” NCT03392571 ↗ “Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W)” NCT06735131 ↗ “nab-Paclitaxel 125mg/m2, ivgtt, days 1 and 8” NCT06991491 ↗ “nab-paclitaxel given weekly or every 3 weeks” NCT05074290 ↗ “Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt)” NCT06230055 ↗ “Nab-paclitaxel 125 mg/m2 i.v. over 30 min” NCT05679050 ↗ “Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07547332 ↗ “Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07432594 ↗ “Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07601737 ↗ “Albumin-Bound Paclitaxel /nab-Paclitaxel” NCT07668453 ↗ “Nab-paclitaxel: 125 mg/m² ，iv，d1、d8，q3w；” NCT06916975 ↗ “standard atezolizumab and nab-paclitaxel” PMID 42128502 ↗ May 2026 “nab-paclitaxel (125mg/ m2, ivgtt, d1, 8)” NCT05481476 ↗ “260 mg/m2 nab-paclitaxel, intravenously” PMID 38048802 ↗ Dec 2023 “nab-paclitaxel 130mg/m2，day 1 and day 8” NCT06176534 ↗ “nab-paclitaxel 260mg/m\^2, IV, days 1” NCT05114720 ↗ “nab-paclitaxel (100mg/m² IV, weekly)” NCT07491822 ↗ “nab-paclitaxel（260mg/m2，q3w）3-4cycle” NCT07089199 ↗ “Nab-paclitaxel：220mg/m2，IV，d1，d22” NCT06452602 ↗ “Drug: nab-paclitaxel IV infusion” NCT05894889 ↗ “Gemcitabine with Nab Paclitaxel” NCT07044453 ↗ “nab-paclitaxel abraxane ABI-007” NCT03051373 ↗ “carboplatin plus nab-paclitaxel” NCT06907602 ↗ “Nab-paclitaxel and Gemcitabine” NCT02707159 ↗ “Atezolizumab + Nab-paclitaxel” NCT06135714 ↗ “nab-paclitaxel 100 mg/m2 i.v.” NCT07715396 ↗ “Nab-Paclitaxel (125mg/m2 IV)” NCT07488884 ↗ “Gemcitabine + nab-paclitaxel” NCT02548169 ↗ “Gemcitabine / nab-paclitaxel” NCT01726582 ↗ “Gemcitabine + nab-paclitaxel” NCT03652428 ↗ “Gemcitabine, nab-Paclitaxel” NCT05601323 ↗ “nab-paclitaxel (260 mg/m2)” NCT06832904 ↗ “Nab-paclitaxel+Epirubicin” NCT06967103 ↗ “nab-paclitaxel (Abraxane)” NCT01715142 ↗ “Abraxane (nab-paclitaxel)” NCT00970996 ↗ “Drug: Nab paclitaxel” NCT04964960 ↗ “Drug: Nab paclitaxel” NCT06017284 ↗ “Drug: Nab paclitaxel” NCT04902261 ↗ “Drug: Nab paclitaxel” NCT04253964 ↗ “Drug: Nab paclitaxel” NCT07057427 ↗ “Drug: Nab paclitaxel” NCT05524974 ↗ “Drug: Nab paclitaxel” NCT04652206 ↗ “Drug: Nab-paclitaxel” NCT05491694 ↗ “nab-paclitaxel” NCT06983743 ↗ |
| Known as | nab-paclitaxel abraxane ABI-007 | “nab-paclitaxel abraxane ABI-007” NCT03051373 ↗ |
| Known as | Nab-Paclitaxel ；Abraxane | “Nab-Paclitaxel ；Abraxane” NCT02272738 ↗1“Nab paclitaxel: Abraxane” NCT01802970 ↗ |
| Known as | Nab-PTX | “This study evaluates the activity and safety of neoadjuvant nanoparticle albumin-bound paclitaxel (nab-PTX) plus trastuzumab for pure HER2 breast cancer in patients with low...” PMID 30963212 ↗ Apr 20194“We aimed to study the tolerability, safety, pharmacokinetics, and tumour response of nanoparticle albumin bound paclitaxel (NAB-PTX) during PIPAC in a Phase I study.” PMID 35843174 ↗ Jul 2022 “Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1” NCT04581265 ↗ “Nab-paclitaxel (Nab-PTX) is a novel albumin-bound paclitaxel with a superior therapeutic index to docetaxel.” NCT04850235 ↗ “Albumin Paclitaxel，260mg/m2 IV every 3 weeks D1, 8(Q3W)，Other Name: Nab-PTX” NCT05833971 ↗ |
| Known as | nab1-paclitaxel | “Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer” NCT02620800 ↗ |
| Known as | NanoPac | “NanoPac is very small (submicron) particles of the chemotherapy drug, paclitaxel, which is administered intravenously in a number of types of cancer.” NCT04314895 ↗6“NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)” NCT03188991 ↗ |
| Known as | Nanoparticle Albumin Bound (Nab) Paclitaxel | “Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer” NCT01830244 ↗ |
| Known as | nanoparticle albumin-bound paclitaxel | “PURPOSE: This multicenter phase II trial evaluated the efficacy and safety of weekly nanoparticle albumin-bound paclitaxel with carboplatin and weekly trastuzumab as first-line...” PMID 20705560 ↗ Aug 201021“The objective of this single-arm phase II trial was to evaluate the benefit of neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel plus 5-fluorouracil in...” NCT02033538 ↗ “Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is an optimized and improved derivative of paclitaxel with superior efficacy and fewer adverse reactions, and it is...” PMID 37201078 ↗ Apr 2023 “This study evaluates the activity and safety of neoadjuvant nanoparticle albumin-bound paclitaxel (nab-PTX) plus trastuzumab for pure HER2 breast cancer in patients with low...” PMID 30963212 ↗ Apr 2019 “Nanoparticle albumin bound paclitaxel is reported to achieve a higher intracellular tumour paclitaxel concentration via the albumin mediated transendothelial transport system” NCT01830244 ↗ “Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Nanoparticle Albumin Bound-Paclitaxel) in Patients With Advanced Solid Tumors” NCT00499291 ↗ “BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel) is an alternative to standard taxanes for breast cancer (BC) treatment.” PMID 28701571 ↗ Jul 2017 “Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.” NCT03636308 ↗ “Nab-paclitaxel, also known as nanoparticle albumin-bound paclitaxel, is a chemotherapy drug used to treat certain cancers.” NCT07134413 ↗ “Take nanoparticlealbumin-bound paclitaxel (125mg/m2, d1) per week for 3 weeks as one cycle for 4 cycles with Toripalimab” NCT04418154 ↗ “Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8” NCT03051373 ↗ “gemcitabine and nanoparticle albumin bound paclitaxel (nab-paclitaxel) every 14 days for 4 cycles” NCT02626520 ↗ “Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.” NCT00124943 ↗ “Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15” NCT03401827 ↗ “nanoparticle albumin-bound paclitaxel (nab (®)-paclitaxel)” PMID 27411683 ↗ Jul 2016 |
| Known as | Nanoparticle Paclitaxel | “Drug: Nanoparticle Paclitaxel” NCT00124943 ↗ |
| Known as | Nanoxel | “Nanoxel (Paclitaxel Nanoparticle formulation )” NCT00915369 ↗ |
| Known as | NSC #673089 | “A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and...” NCT00079430 ↗4“Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or...” NCT00687687 ↗ “A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent...” NCT00276796 ↗ “OUTLINE: Single-Agent Chemotherapy. Paclitaxel, TAX, NSC-673089.” NCT00002562 ↗ “Paclitaxel (Taxol, NSC # 673089)” NCT00112489 ↗ |
| Known as | NSC-125973 | “OUTLINE: Single-Agent Chemotherapy. Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.” NCT00002632 ↗3“plus Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.” NCT00001442 ↗ “Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875” NCT00001499 ↗ “Paclitaxel (Bristol-Myers), Taxol, NSC-125973.” NCT00002568 ↗ |
| Known as | oPac | “oral paclitaxel plus E (oPac + E)” PMID 35858154 ↗ Jul 2022 |
| Known as | Oral Paclitaxel Solution | “Oral Paclitaxel Solution: 200 mg/m² administered on a 21-day cycle, with oral doses given on Day 1 and Day 8 of each cycle, taken twice daily (morning and evening).” NCT07599163 ↗ |
| Known as | PAB | “This study aimed to compare SYHX2011 and paclitaxel for injection (albumin-bound) (PAB) in patients with breast cancer.” PMID 42368972 ↗ Jun 2026 |
| Known as | PAC | “with the EGFR signaling inhibitor gefitinib (GEF) combined with weekly intravenous paclitaxel (PAC) and radiation therapy (RT).” PMID 19879702 ↗ Oct 20093“ipatasertib (ipat) in combination with atezolizumab (atezo) and paclitaxel (pac) or nab-paclitaxel” NCT03800836 ↗ “gemcitabine (Gem)/nab- paclitaxel (PAC)” NCT02125136 ↗ “paclitaxel (PAC)” NCT07546812 ↗ |
| Known as | Paclimer | “A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.” PMID 16626792 ↗ Apr 2006 |
| Known as | Paclitaxcel | “Neoadjuvant therapy with Paclitaxcel of 260mg/m2, iv, qd, on day 1, 22” NCT04473716 ↗ |
| Known as | Paclitaxel (albumin-bound) | “Compare the effectiveness and safety of paclitaxel (albumin-bound) combined with radiotherapy and cisplatin combined with radiotherapy in the treatment of early nasopharyngeal...” NCT04766359 ↗8“All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy” NCT03830385 ↗ “Paclitaxel (albumin-bound) at 125 mg/m² and gemcitabine at 1000 mg/m² will be administered via intravenous infusion” NCT07259590 ↗ “Paclitaxel (albumin-bound) 130 mg/m2, i.v., d1, 8; Carboplatin AUC 5, i.v. d1; repeat every 21days, 6 cycles.” NCT04661696 ↗ “Paclitaxel (albumin bound), intravenously, over 30 min on day 1, day 8 and day 15 of every 28-day cycle” NCT05047991 ↗ “Paclitaxel albumin-bound injection: 100 mg per vial; 260 mg/m² intravenously every 3 weeks” NCT07492342 ↗ “Paclitaxel (Albumin bound): 260 mg/m2, administered by IV infusion every 3 weeks” NCT04760431 ↗ “Paclitaxel (albumin-bound)” NCT07392346 ↗ “Paclitaxel (albumin-bound)” NCT04443036 ↗ |
| Known as | Paclitaxel (Taxol, Abraxane) | “Paclitaxel (Taxol, Abraxane)” NCT00659269 ↗ |
| Known as | Paclitaxel albumin | “combined regimen of Durvalumab (anti-PD-L1 antibody), Lenvatinib and Paclitaxel albumin (nab-paclitaxel).” NCT05327582 ↗19“Paclitaxel-albumin 250mg/m2 ivgtt d1 Q3w or 125mg/m2 ivgtt d1,d8 Q3w” NCT06955156 ↗ “nab-paclitaxel (paclitaxel-albumin) + carboplatin” NCT02658214 ↗ “paclitaxel-albumin 150\~180 mg/m2, i.v. d1,q3w” NCT05738434 ↗ |
| Known as | paclitaxel albumin-stabilized nanoparticle formulation | “To determine the maximum tolerated dose and recommended phase II dose of dovitinib (dovitinib lactate) when administered concurrently with gemcitabine (gemcitabine...” NCT02048943 ↗9“To evaluate the efficacy (overall response rate) of single agent nab-paclitaxel (Abraxane) (paclitaxel albumin-stabilized nanoparticle formulation) in patients with relapsed or...” NCT01646762 ↗ “nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation)” NCT02194829 ↗ “Drug: paclitaxel albumin-stabilized nanoparticle formulation” NCT00662129 ↗ |
| Known as | Paclitaxel for Injection | “Paclitaxel for Injection” NCT07229586 ↗ |
| Known as | Paclitaxel for injection (albumin binding) | “Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1” NCT04067102 ↗ |
| Known as | Paclitaxel for Injection (Albumin-bound) | “Paclitaxel for injection (albumin-bound) uses human serum albumin as the carrier to avoid the use of organic solvents for intravenous injection of paclitaxel, reducing the...” NCT04766827 ↗4“Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)” NCT04017377 ↗ “Paclitaxel for Injection (Albumin-bound): 125 mg/m² on Days 1 and 8, every 3 weeks per cycle.” NCT07240766 ↗ “Drug: Paclitaxel for Injection（Albumin Bound）” NCT01494415 ↗ “Paclitaxel for injection(Albumin Bound)” NCT04443036 ↗ |
| Known as | Paclitaxel For Injection(Aalbumin Bound） | “(NAB)-paclitaxel plus Cisolation (Paclitaxel For Injection(Aalbumin Bound）125 mg/m2 Day 1 、Day8” NCT05816694 ↗ |
| Known as | Paclitaxel Injection | “Paclitaxel Injection: 50mg/m², iv, D1, D8; Q3W;” NCT07304258 ↗ |
| Known as | Paclitaxel Micelles | “Paclitaxel Micelles: 230 mg/m² (C1), then 300 mg/m² if tolerated, IV (≥3h), D8, Q3W.” NCT07359053 ↗ |
| Known as | Paclitaxel Polymeric Micelles for Injection | “Paclitaxel Polymeric Micelles for Injection：150mg / m2 intravenously over 3 hours on Days1,8 of each 21-day cycle.” NCT06706895 ↗ |
| Known as | Paclitaxel Protein Bound | “Paclitaxel Protein Bound (Abraxane)” NCT03138720 ↗ |
| Known as | Paclitaxel protein-bound particles | “Paclitaxel protein-bound particles (Abraxane®) 260 mg/m\^2 IV” NCT00262067 ↗ |
| Known as | Paclitaxel(Sawai),(NK) | “Paclitaxel(Sawai),(NK), Paraplatin(BMS), Carboplatin(SANDOZ)” NCT01506856 ↗ |
| Known as | Paclitaxel-albumin Injection | “Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection” NCT04181645 ↗ |
| Known as | Paclitaxel: Taxol | “Paclitaxel (Taxol®)” NCT02983045 ↗3“paclitaxel (Taxol)” NCT02059876 ↗ “Paclitaxel: Taxol” NCT00840450 ↗ “Paclitaxel, Taxol” NCT00873119 ↗ |
| Known as | Paclitaxol | “Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles” NCT03242551 ↗1“Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks” NCT03144843 ↗ |
| Known as | PAX | “Preclinical and clinical investigation of the combination of the antiangiogenesis/anti-invasion agent carboxyamido-triazole (CAI) administered with the cytotoxic agent paclitaxel (PAX).” PMID 11410496 ↗ Jun 2001 |
| Known as | Phyxol | “Paclitaxel (Phyxol) , Cisplatin” NCT00154882 ↗1“Phyxol(Paclitaxel)” NCT00823186 ↗ |
| Known as | PICS | “Paclitaxel Injection Concentrate for Suspension (PICS)” NCT04332549 ↗ |
| Known as | pm-Pac | “Polymeric micellar paclitaxel (pm-Pac) is a novel Cremophor EL-free,” PMID 33130217 ↗ Oct 2020 |
| Known as | PNU-93914 | “PNU-93914 (Liposome Encapsulated Paclitaxel)” NCT00016900 ↗ |
| Known as | Polymeric micellar paclitaxel | “Polymeric micellar paclitaxel (pm-Pac) is a novel Cremophor EL-free,” PMID 33130217 ↗ Oct 2020 |
| Known as | Protein bound paclitaxel | “Protein bound paclitaxel is a novel paclitaxel combined of paclitaxel and albumin by nanotechnology” NCT03585062 ↗ |
| Known as | PTX | “To investigate the efficacy and safety of apatinib in combination with paclitaxel (PTX) alone or POF (PTX, oxaliplatin, and 5-fluorouracil) in patients with taxane-resistant...” PMID 33178765 ↗ Oct 202016“By detecting the blood concentration of paclitaxel (PTX), Investigator assume this research can identify the individual differences of PTX pharmacokinetics (PK) parameters” NCT02737709 ↗ “Paclitaxel plus Carboplatin (TC) therapy; Paclitaxel (PTX) 175 mg/m2 + Carboplatin(CBDCA) area under curve(AUC) 6 q3weeks day1, 3 to 6 cycles” NCT04063527 ↗ “BACKGROUND: NK105 is a novel nanoparticle drug delivery formulation that encapsulates paclitaxel (PTX) in polymeric micelles.” PMID 30745582 ↗ Feb 2019 “Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases.” NCT05966441 ↗ “Paclitaxel (PTX) is one of the most potent and commonly used chemotherapies for breast and pancreatic cancer.” PMID 35552677 ↗ Jul 2022 “paclitaxel (PTX) (20 mg/m2 intraperitoneally and 50 mg/m2 intravenously on days 1 and 8)” NCT05204173 ↗ “Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen).” NCT03544047 ↗ “paclitaxel (PTX) 175 mg/m2 every 3 weeks or paclitaxel (PTX) 80 mg/m2 every week” NCT04172259 ↗ “Drug: Paclitaxel (PTX). Name of Device: Advance PTX” NCT05173857 ↗ “Paclitaxel (PTX) is a common chemotherapeutic agent” NCT06818331 ↗ “Drug: Paclitaxel Dose: 135mg/m2 Other Name: PTX” NCT05171530 ↗ “TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin” NCT02934828 ↗ “C: cyclophosphamide (CTX） T: paclitaxel (PTX）” NCT03876886 ↗ “using paclitaxel (PTX) plus oxaliplatin (OHP)” NCT02607982 ↗ “Drug: paclitaxel (PTX)” NCT04109066 ↗ “Paclitaxel (PTX)” NCT01435018 ↗ |
| Known as | S-8184 | “S-8184 Paclitaxel Injectable Emulsion” NCT00034190 ↗2“S-8184 Paclitaxel Injectable Emulsion” NCT00034177 ↗ “S-8184 Paclitaxel Injectable Emulsion” NCT00034151 ↗ |
| Known as | S-8184 Paclitaxel Injectable Emulsion | “A Phase 2 Multicenter Evaluation of the Safety and Efficacy of TOCOSOL(TM) Paclitaxel (S-8184 Paclitaxel Injectable Emulsion) in Patients With Metastatic or Locally Advanced,...” NCT00077688 ↗ |
| Known as | sb-Pac | “solvent-based paclitaxel (sb-Pac) plus cisplatin” PMID 33130217 ↗ Oct 2020 |
| Known as | sb-paclitaxel | “PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus...” PMID 22547591 ↗ Apr 2012 |
| Known as | SMET12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06208033 ↗ |
| Known as | SMS001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06693336 ↗ |
| Known as | solvent-based paclitaxel | “PURPOSE: This phase III trial compared the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) plus carboplatin with solvent-based paclitaxel (sb-paclitaxel) plus...” PMID 22547591 ↗ Apr 20121“solvent-based paclitaxel (sb-Pac) plus cisplatin” PMID 33130217 ↗ Oct 2020 |
| Known as | SOR007 | “This Phase 1/2 study evaluated safety and efficacy of a topical submicron particle paclitaxel (SPP) in an anhydrous ointment base (SOR007), primarily in breast cancer patients...” PMID 35471470 ↗ Apr 20221“SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment” NCT03083470 ↗ |
| Known as | SPP | “This Phase 1/2 study evaluated safety and efficacy of a topical submicron particle paclitaxel (SPP) in an anhydrous ointment base (SOR007), primarily in breast cancer patients...” PMID 35471470 ↗ Apr 2022 |
| Known as | SYHX2011 | “Albumin-Bound Paclitaxel (SYHX2011) in Patients with Advanced Breast Cancer: A Multicenter, Randomized, Double-Blind, Phase III Study.” PMID 42368972 ↗ Jun 2026 |
| Known as | Systemic therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03904927 ↗ |
| Known as | TAX | “OBJECTIVES: I. Determine a safe weekly dose of intravenous estramustine (EM) in combination with paclitaxel (TAX) and carboplatin (CBDCA) in patients with advanced prostate cancer.” NCT00003394 ↗6“Patients also receive paclitaxel (TAX) as a weekly 3 hour infusion on days 1, 8, 15, and 29” NCT00002984 ↗ “OUTLINE: Single-Agent Chemotherapy. Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.” NCT00002632 ↗ “Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875” NCT00001499 ↗ “plus Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.” NCT00001442 ↗ “TAX Paclitaxel (Bristol-Myers)” NCT00002711 ↗ “TAX(Taxol)” NCT05871918 ↗ |
| Known as | Taxol | “Dose-dense weekly paclitaxel (Taxol) and carboplatin (dd-TC) improved survival compared with conventional tri-weekly paclitaxel and carboplatin (c-TC) as a first-line...” PMID 24356636 ↗ Jan 201482“The purpose of this study is to determine whether a new chemotherapy schedule using biweekly combination of paclitaxel (Taxol®), gemcitabine (Gemzar®) and Avastin would help to...” NCT00618826 ↗ “The purpose of this study is to compare the objective response rates of patients randomized to receive either TOCOSOL(R) Paclitaxel or Taxol(R) (paclitaxel injection)...” NCT00251095 ↗ “The purpose of this study is to find out what effects, good and bad, the chemotherapy drugs gemcitabine (Gemzar) and paclitaxel (Taxol) have in combination with twice daily...” NCT00226746 ↗ “ABI-007 is a new anticancer medication containing the same active ingredient as Taxol, paclitaxel, but formulated as a protein-stabilized material that is suspended in salt...” NCT00046527 ↗ “Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or...” NCT00687687 ↗ “The front-line treatment consists in a combination of epirubicin, (100 mg/m² in a 30-minute infusion), and paclitaxel (Taxol, 250 mg/m² given in a 3-hour infusion),...” NCT00231582 ↗ “A Phase II Study of Weekly Paclitaxel(Taxol)and 24-Hour Infusion High-Dose 5-Fluorouracil and Leucovorin(HDFL)in the Treatment Locally Advanced and Recurrent/Metastatic Gastric Cancers” NCT00154726 ↗ “Randomized, Crossover, Pharmacokinetic Study Of Paclitaxel (Taxol) And ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle Paclitaxel) In Patients With Advanced Solid Tumors” NCT00095914 ↗ “A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)” NCT00936702 ↗ “BACKGROUND: To evaluate the activity and safety of nonanthracycline-containing weekly PCb [paclitaxel (Taxol) plus carboplatin] regimen in neoadjuvant treatment of breast cancer.” PMID 20211870 ↗ Mar 2010 “A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium” NCT00310011 ↗ “Patients will recieve 3 cycles of carboplatin and gemcitabine followed by 3 cycles of taxol and carboplatin and then three cycles of adriamycin and topotecan.” NCT00157560 ↗ “the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy” PMID 19060587 ↗ Dec 2008 “A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer” NCT00003327 ↗ “Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) given at a dose of 175 mg/m2 every 3 weeks as a 3- to 4-hour outpatient infusion” PMID 7636549 ↗ Aug 1995 “A Phase II Study Of Irinotecan (Camptosar) And Paclitaxel (Taxol) In Patients With Adenocarcinoma Of The Upper Gastrointestinal Tract” NCT00020761 ↗ “A Phase II Trial of External Irradiation (50.4 GY) and Weekly Paclitaxel (Taxol) for Non-Metastatic, Unresectable Pancreatic Cancer” NCT00003591 ↗ “Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy” NCT00001387 ↗ “Paclitaxel (currently marketed as Taxol) is an anti-microtubular network agent and is active in a broad spectrum of malignancies.” NCT01190982 ↗ “chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist that the oncologist considers most useful” NCT06922279 ↗ “LEP-ETU is a new formulation of the anti-cancer agent paclitaxel for injection or Taxol (paclitaxel and Cremophor EL).” NCT00080418 ↗ “The two drug combination, carboplatin (Paraplatin) and paclitaxel (Taxol), is commonly used as the first treatment.” NCT00161278 ↗ “EVALUATION OF PACLITAXEL (TAXOL) IN PERSISTENT OR RECURRENT NON-SQUAMOUS CELL CARCINOMA OF THE CERVIX AND VAGINA” NCT00002562 ↗ “Evaluation of Paclitaxel (Taxol) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus” NCT00003054 ↗ “Weekly 1-Hour Paclitaxel (Taxol) Plus Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin)” NCT00003539 ↗ “patients with advanced vulvar cancer received paclitaxel (Taxol) every 3 weeks for up to 10 cycles.” PMID 19487487 ↗ Jun 2009 “standard paclitaxel [Taxol® (Bristol-Myers Squibb GmbH), or equivalent generic formulation]” PMID 24667715 ↗ Apr 2014 “Weekly taxol (paclitaxel) is widely used in breast cancer patients with metastatic disease.” NCT00353717 ↗ “A PHASE I STUDY OF PROLONGED LOW-DOSE TOPOTECAN INFUSION COMBINED WITH PACLITAXEL (TAXOL)” NCT00002587 ↗ “Phase II Trial of Gemcitabine/Paraplatin® (Carboplatin) Followed by Taxol® (Paclitaxel)” NCT00276588 ↗ “OUTLINE: Single-Agent Chemotherapy. Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.” NCT00002632 ↗ “Paclitaxel (also called Taxol) is an FDA drug approved for breast cancer patients.” NCT02041429 ↗ “Paclitaxel (Taxol) 90 mg/m\^2 IV every week for 3 weeks followed by 1 week of rest” NCT00281697 ↗ “Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol)” NCT03961698 ↗ “Subsequent Taxol cycles (Paclitaxel 80mg/m2 IV) once weekly for 12 weeks.” NCT04170465 ↗ “and paclitaxel (Taxol) in advanced, untreated non-small-cell lung cancer” PMID 22904239 ↗ Aug 2012 “paclitaxel, i.e. 65 and 63 in the original (Taxol) and generic arms” PMID 27997900 ↗ Dec 2016 “Chemotherapy drug of liver metastases is oxaliplatin and taxol.” NCT02233205 ↗ “2 drugs called cisplatin and paclitaxel (also known as Taxol).” NCT00588237 ↗ “One drug is a chemotherapy agent called paclitaxel (Taxol®).” NCT01276041 ↗ “plus Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.” NCT00001442 ↗ “Paclitaxel (Taxol) 80mg/m2, IV every week of 12 cycles” NCT06531447 ↗ “Taxol(Paclitaxel) and Carboplatin(Paraplatin) Regimen” NCT00035152 ↗ “Taxol, Epirubincin, with or without Cyclophosphamide” NCT02842099 ↗ “Paclitaxel (Bristol-Myers), Taxol, NSC-125973.” NCT00002568 ↗ “conventional Paclitaxel formulations (Taxol®)” NCT06867562 ↗ “paclitaxel (Taxol®, Bristol-Myers Squibb)” NCT00493025 ↗ “IV paclitaxel (as Taxol or generic).” NCT02594371 ↗ “Carboplatin and Taxol (paclitaxel)” NCT02297217 ↗ “* BIBW 2992 and paclitaxel (Taxol)” NCT00809133 ↗ “Paclitaxel (Taxol, NSC # 673089)” NCT00112489 ↗ “Taxol (Paclitaxel Injection)” NCT04889768 ↗ “paclitaxel injection (Taxol)” NCT06078670 ↗ “Taxol (80mg/m2) 1/7d x 12w” NCT05871918 ↗ “Taxol (paclitaxel)” NCT00449657 ↗ “Paclitaxel (Taxol)” NCT06620029 ↗ “paclitaxel (Taxol)” NCT00003582 ↗ “Paclitaxel (Taxol)” NCT00038246 ↗ |
| Known as | Taxol (Paclitaxel) | “Taxol (Paclitaxel)” NCT02195973 ↗3“taxol (paclitaxel)” NCT00518583 ↗ “Taxol (paclitaxel)” NCT01653912 ↗ “Taxol (Paclitaxel)” NCT00249964 ↗ |
| Known as | Taxol (Registered Trademark) | “infusional Taxol® (Registered Trademark) (paclitaxel)” NCT00001384 ↗ |
| Known as | Taxol R | “This is a Phase II study of paclitaxel (Taxol R) administered as a 96-hour (4 day) continuous infusion followed by a bolus of cisplatin for previously untreated patients with...” NCT00001450 ↗ |
| Known as | Teggio | “Teggio” NCT05385900 ↗ |
| Known as | TOCOSOL | “Experimental Arm: TOCOSOL Paclitaxel” NCT00034177 ↗ |
| Known as | TSN1611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385925 ↗ |
| Known as | ZhusheyongZishanchun(Baidanbai Jiehexing) | “Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)” NCT04017377 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.” NCT00091039 ↗ |
| Modality | Small molecule | “Chemotherapy with a platinum agent and a taxane (paclitaxel) is considered the standard of care for treatment of ovarian carcinoma.” PMID 15547181 ↗ Nov 2004 |
| Route | Intravenous | “continuous IV infusion of 120 mg/m(2) over 120 hours” NCT00001442 ↗ |
| Target | SPARC | “Nab-paclitaxel, an albumin bound nano formulation of paclitaxel that targets SPARC” NCT01442974 ↗ |